### International Standard for Results Management

The World Anti-Doping Code International Standard for Results Management is a mandatory International Standard developed as part of the World Anti-Doping Program. It was developed in consultation with Signatories, public authorities, and other relevant stakeholders.

The International Standard for Results Management was first adopted and approved by the WADA Executive Committee at the World Conference on Doping in Sport in Katowice on 7 November 2019 and is effective as of 1 January 2021.

Published by:
World Anti-Doping Agency
Stock Exchange Tower
800 Place Victoria (Suite 1700)
PO Box 120
Montreal, Quebec
Canada H4Z 1B7
[www.wada-ama.org](http://www.wada-ama.org)
Tel: +1 514 904 9232
Fax: +1 514 904 8650
E-mail: code@wada-ama.org

### PART ONE: INTRODUCTION, CODE PROVISIONS, INTERNATIONAL STANDARD PROVISIONS AND DEFINITIONS

#### 1.0 Introduction and Scope

The International Standard for Results Management is a mandatory International Standard developed as part of the World Anti-Doping Program.

The purpose of the International Standard for Results Management is to set out the core responsibilities of Anti-Doping Organizations with respect to Results Management. In addition to describing certain general principles of Results Management (section 4), this International Standard also sets out the core obligations applicable to the various phases of Results Management from the initial review and notification of potential anti-doping rule violations (section 5), through Provisional Suspensions (section 6), the assertion of anti-doping rule violations and proposal of Consequences (section 7), the Hearing Process (section 8) until the issuance and notification of the decision (section 9) and appeal (section 10).
Notwithstanding the mandatory nature of this *International Standard* and the possibility that departures by *Anti-Doping Organizations* may give rise to compliance consequences under the *International Standard for Code Compliance by Signatories*, departures from this *International Standard* shall not invalidate analytical results or other evidence of an anti-doping rule violation and shall not constitute a defense to an anti-doping rule violation, except as expressly provided for under *Code* Article 3.2.3.

Terms used in this *International Standard* that are defined terms from the *Code* are italicized. Terms that are defined in this or another *International Standard* are underlined.

### 2.0 Code Provisions

The following articles in the 2021 *Code* are directly relevant to the *International Standard for Results Management*, they can be obtained by referring to the *Code* itself:

- *Code* Article 2 Anti-Doping Rule Violations
- *Code* Article 3 Proof of Doping
- *Code* Article 5 Testing and Investigations
- *Code* Article 7 Results Management: Responsibility, Initial Review, Notice and Provisional Suspensions
- *Code* Article 8 Results Management: Right to a Fair Hearing and Notice of Hearing Decision
- *Code* Article 9 Automatic Disqualification of Individual Results
- *Code* Article 10 Sanctions on Individuals
- *Code* Article 11 Consequences to Teams
- *Code* Article 13 Results Management: Appeals
- *Code* Article 14 Confidentiality and Reporting
- *Code* Article 15 Implementation of Decisions
- *Code* Article 20 Additional Roles and Responsibilities of Signatories and *WADA*

### 3.0 Definitions and Interpretation

#### 3.1 Defined Terms from the 2021 *Code* that are used in the *International Standard for Results Management*

**ADAMS:** The Anti-Doping Administration and Management System is a Web-based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and *WADA* in their anti-doping operations in conjunction with data protection legislation.

**Administration:** Providing, supplying, supervising, facilitating, or otherwise participating in the *Use* or *Attempted Use* by another *Person* of a *Prohibited Substance* or *Prohibited Method*. However, this definition shall not include the actions of bona fide medical personnel.
involving a Prohibited Substance or Prohibited Method used for genuine and legal therapeutic purposes or other acceptable justification and shall not include actions involving Prohibited Substances which are not prohibited in Out-of-Competition Testing unless the circumstances as a whole demonstrate that such Prohibited Substances are not intended for genuine and legal therapeutic purposes or are intended to enhance sport performance.

**Adverse Analytical Finding:** A report from a WADA-accredited laboratory or other WADA-approved laboratory that, consistent with the International Standard for Laboratories establishes in a Sample the presence of a Prohibited Substance or its Metabolites or Markers or evidence of the Use of a Prohibited Method.

**Adverse Passport Finding:** A report identified as an Adverse Passport Finding as described in the applicable International Standards.

**Anti-Doping Organization:** WADA or a Signatory that is responsible for adopting rules for initiating, implementing or enforcing any part of the Doping Control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other Major Event Organizations that conduct Testing at their Events, International Federations, and National Anti-Doping Organizations.

**Athlete:** Any Person who competes in sport at the international level (as defined by each International Federation) or the national level (as defined by each National Anti-Doping Organization). An Anti-Doping Organization has discretion to apply anti-doping rules to an Athlete who is neither an International-Level Athlete nor a National-Level Athlete, and thus to bring them within the definition of “Athlete”. In relation to Athletes who are neither International-Level nor National-Level Athletes, an Anti-Doping Organization may elect to: conduct limited Testing or no Testing at all; analyze Samples for less than the full menu of Prohibited Substances; require limited or no whereabouts information; or not require advance TUEs. However, if an Article 2.1, 2.3 or 2.5 anti-doping rule violation is committed by any Athlete over whom an Anti-Doping Organization has elected to exercise its authority to test and who competes below the international or national level, then the Consequences set forth in the Code must be applied. For purposes of Article 2.8 and Article 2.9 and for purposes of anti-doping information and Education, any Person who participates in sport under the authority of any Signatory, government, or other sports organization accepting the Code is an Athlete.

[Comment to Athlete: Individuals who participate in sport may fall in one of five categories: 1) International-Level Athlete, 2) National-Level Athlete, 3) individuals who are not International or National-Level Athletes but over whom the International Federation or National Anti-Doping Organization has chosen to exercise authority, 4) Recreational Athlete, and 5) individuals over
whom no International Federation or National Anti-Doping Organization has, or has chosen to, exercise authority. All International and National-Level Athletes are subject to the anti-doping rules of the Code, with the precise definitions of international and national level sport to be set forth in the anti-doping rules of the International Federations and National Anti-Doping Organizations.

**Athlete Biological Passport:** The program and methods of gathering and collating data as described in the International Standard for Testing and Investigations and International Standard for Laboratories.

**Attempt:** Purposely engaging in conduct that constitutes a substantial step in a course of conduct planned to culminate in the commission of an anti-doping rule violation. Provided, however, there shall be no anti-doping rule violation based solely on an Attempt to commit a violation if the Person renounces the Attempt prior to it being discovered by a third party not involved in the Attempt.

**Atypical Finding:** A report from a WADA-accredited laboratory or other WADA-approved laboratory which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an Adverse Analytical Finding.

**Atypical Passport Finding:** A report described as an Atypical Passport Finding as described in the applicable International Standards.

**CAS:** The Court of Arbitration for Sport.

**Code:** The World Anti-Doping Code.

**Competition:** A single race, match, game or singular sport contest. For example, a basketball game or the finals of the Olympic 100-meter race in athletics. For stage races and other sport contests where prizes are awarded on a daily or other interim basis the distinction between a Competition and an Event will be as provided in the rules of the applicable International Federation.

**Consequences of Anti-Doping Rule Violations (“Consequences”):** An Athlete’s or other Person’s violation of an anti-doping rule may result in one or more of the following: (a) Disqualification means the Athlete’s results in a particular Competition or Event are invalidated, with all resulting Consequences including forfeiture of any medals, points and prizes; (b) Ineligibility means the Athlete or other Person is barred on account of an anti-doping rule violation for a specified period of time from participating in any Competition or other activity or funding as provided in Article 10.14.1; (c) Provisional Suspension means the Athlete or other Person is barred temporarily from participating in any Competition or activity prior to the final decision at a hearing conducted under Article 8; (d) Financial Consequences means a financial sanction imposed for an anti-doping rule
violation or to recover costs associated with an anti-doping rule violation; and (e) Public Disclosure means the dissemination or distribution of information to the general public or Persons beyond those Persons entitled to earlier notification in accordance with Article 14. Teams in Team Sports may also be subject to Consequences as provided in Article 11.

**Contaminated Product:** A product that contains a Prohibited Substance that is not disclosed on the product label or in information available in a reasonable Internet search.

**Delegated Third Parties:** Any Person to which an Anti-Doping Organization delegates any aspect of Doping Control or anti-doping Education programs including, but not limited to, third parties or other Anti-Doping Organizations that conduct Sample collection or other Doping Control services or anti-doping educational programs for the Anti-Doping Organization, or individuals serving as independent contractors who perform Doping Control services for the Anti-Doping Organization (e.g., non-employee Doping Control Officers or chaperones). This definition does not include CAS.

**Disqualification:** See Consequences of Anti-Doping Rule Violations above.

**Doping Control:** All steps and processes from test distribution planning through to ultimate disposition of any appeal and the enforcement of Consequences, including all steps and processes in between, including but not limited to, Testing, investigations, whereabouts, TUEs, Sample collection and handling, laboratory analysis, Results Management, hearings and appeals, and investigations or proceedings relating to violations of Article 10.14 (Status During Ineligibility or Provisional Suspension).

**Event:** A series of individual Competitions conducted together under one ruling body (e.g., the Olympic Games, World Championships of an International Federation, or Pan American Games).

**Financial Consequences:** See Consequences of Anti-Doping Rule Violations above.

**In-Competition:** The period commencing at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate through to the end of such Competition and the Sample collection process related to such Competition. Provided, however, WADA may approve, for a particular sport, an alternative definition if an International Federation provides a compelling justification that a different definition is necessary for its sport; upon such approval by WADA, the alternative definition shall be followed by all Major Event Organizations for that particular sport.

\[\text{Comment to In-Competition: Having a universally accepted definition for In-Competition provides greater}\]
harmonization among Athletes across all sports, eliminates or reduces confusion among Athletes about the relevant timeframe for In-Competition Testing, avoids inadvertent Adverse Analytical Findings in between Competitions during an Event and assists in preventing any potential performance enhancement benefits from substances prohibited Out-of-Competition being carried over to the Competition period.]

Ineligibility: See Consequences of Anti-Doping Rule Violations above.

Institutional Independence: Hearing panels on appeal shall be fully Independent Institutionally from the Anti-Doping Organization responsible for Results Management. They must therefore not in any way be administered by, connected or subject to the Anti-Doping Organization responsible for Results Management.

International Event: An Event or Competition where the International Olympic Committee, the International Paralympic Committee, an International Federation, a Major Event Organization, or another international sport organization is the ruling body for the Event or appoints the technical officials for the Event.

International-Level Athlete: Athletes who compete in sport at the international level, as defined by each International Federation, consistent with the International Standard for Testing and Investigations.

[Comment to International-Level Athlete: Consistent with the International Standard for Testing and Investigations, the International Federation is free to determine the criteria it will use to classify Athletes as International-Level Athletes, e.g., by ranking, by participation in particular International Events, by type of license, etc. However, it must publish those criteria in clear and concise form, so that Athletes are able to ascertain quickly and easily when they will become classified as International-Level Athletes. For example, if the criteria include participation in certain International Events, then the International Federation must publish a list of those International Events.]

International Standard: A standard adopted by WADA in support of the Code. Compliance with an International Standard (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the International Standard were performed properly. International Standards shall include any Technical Documents issued pursuant to the International Standard.

Major Event Organizations: The continental associations of National Olympic Committees and other international multi-sport organizations that function as the ruling body for any continental, regional or other International Event.

Marker: A compound, group of compounds or biological
variable(s) that indicates the Use of a Prohibited Substance or Prohibited Method.

**Minor:** A natural Person who has not reached the age of eighteen years.

**National Anti-Doping Organization:** The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of Samples, the management of test results, and the conduct of hearings at the national level. If this designation has not been made by the competent public authority(ies), the entity shall be the country's National Olympic Committee or its designee.

**National-Level Athlete:** Athletes who compete in sport at the national level, as defined by each National Anti-Doping Organization, consistent with the International Standard for Testing and Investigations.

**Operational Independence:** This means that (1) board members, staff members, commission members, consultants and officials of the Anti-Doping Organization with responsibility for Results Management or its affiliates (e.g., member federation or confederation), as well as any Person involved in the investigation and pre-adjudication of the matter cannot be appointed as members and/or clerks (to the extent that such clerk is involved in the deliberation process and/or drafting of any decision) of hearing panels of that Anti-Doping Organization with responsibility for Results Management and (2) hearing panels shall be in a position to conduct the hearing and decision-making process without interference from the Anti-Doping Organization or any third party. The objective is to ensure that members of the hearing panel or individuals otherwise involved in the decision of the hearing panel, are not involved in the investigation of, or decisions to proceed with, the case.

**Out-of-Competition:** Any period which is not In-Competition.

**Person:** A natural Person or an organization or other entity.

**Possession:** The actual, physical Possession, or the constructive Possession (which shall be found only if the Person has exclusive control or intends to exercise control over the Prohibited Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited Method exists); provided, however, that if the Person does not have exclusive control over the Prohibited Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited Method exists, constructive Possession shall only be found if the Person knew about the presence of the Prohibited Substance or Prohibited Method and intended to exercise control over it. Provided, however, there shall be no anti-doping rule violation based solely on Possession if, prior to receiving notification of any kind that the Person has committed an
anti-doping rule violation, the Person has taken concrete action demonstrating that the Person never intended to have Possession and has renounced Possession by explicitly declaring it to an Anti-Doping Organization. Notwithstanding anything to the contrary in this definition, the purchase (including by any electronic or other means) of a Prohibited Substance or Prohibited Method constitutes Possession by the Person who makes the purchase.

/Comment to Possession: Under this definition, anabolic steroids found in an Athlete’s car would constitute a violation unless the Athlete establishes that someone else used the car; in that event, the Anti-Doping Organization must establish that, even though the Athlete did not have exclusive control over the car, the Athlete knew about the anabolic steroids and intended to have control over them. Similarly, in the example of anabolic steroids found in a home medicine cabinet under the joint control of an Athlete and spouse, the Anti-Doping Organization must establish that the Athlete knew the anabolic steroids were in the cabinet and that the Athlete intended to exercise control over them. The act of purchasing a Prohibited Substance alone constitutes Possession, even where, for example, the product does not arrive, is received by someone else, or is sent to a third-party address.]

Prohibited List: The List identifying the Prohibited Substances and Prohibited Methods.

Prohibited Method: Any method so described on the Prohibited List.

Prohibited Substance: Any substance, or class of substances, so described on the Prohibited List.

Provisional Hearing: For purposes of Article 7.4.3, an expedited abbreviated hearing occurring prior to a hearing under Article 10 that provides the Athlete with notice and an opportunity to be heard in either written or oral form.

/Comment to Provisional Hearing: A Provisional Hearing is only a preliminary proceeding which may not involve a full review of the facts of the case. Following a Provisional Hearing, the Athlete remains entitled to a subsequent full hearing on the merits of the case. By contrast, an “expedited hearing,” as that term is used in Article 7.4.3, is a full hearing on the merits conducted on an expedited time schedule.]

Provisional Suspension: See Consequences of Anti-Doping Rule Violations above.

Publicly Disclose: See Consequences of Anti-Doping Rule Violations above.

Registered Testing Pool: The pool of highest-priority Athletes established separately at the international level by International Federations and at the national level by National Anti-Doping Organizations, who are subject to focused In-Competition and Out-of-Competition Testing as
part of that International Federation’s or National Anti-Doping Organization’s test distribution plan and therefore are required to provide whereabouts information as provided in Article 5.5 and the International Standard for Testing and Investigations.

**Results Management:** The process encompassing the timeframe between notification as per Article 5 of the International Standard for Results Management, or in certain cases (e.g., Atypical Finding, Athlete Biological Passport, Whereabouts Failure), such pre-notification steps expressly provided for in Article 5 of the International Standard for Results Management, through the charge until the final resolution of the matter, including the end of the hearing process at first instance or on appeal (if an appeal was lodged).

**Sample or Specimen:** Any biological material collected for the purposes of Doping Control.

[Comment to Sample or Specimen: It has sometimes been claimed that the collection of blood Samples violates the tenets of certain religious or cultural groups. It has been determined that there is no basis for any such claim.]

**Signatories:** Those entities accepting the Code and agreeing to implement the Code, as provided in Article 23.

**Specified Method:** See Article 4.2.2.

**Specified Substance:** See Article 4.2.2.

**Substance of Abuse:** See Article 4.2.3.

**Substantial Assistance:** For purposes of Article 10.7.1, a Person providing Substantial Assistance must: (1) fully disclose in a signed written statement or recorded interview all information he or she possesses in relation to anti-doping rule violations or other proceeding described in Article 10.7.1.1, and (2) fully cooperate with the investigation and adjudication of any case or matter related to that information, including, for example, presenting testimony at a hearing if requested to do so by an Anti-Doping Organization or hearing panel. Further, the information provided must be credible and must comprise an important part of any case or proceeding which is initiated or, if no case or proceeding is initiated, must have provided a sufficient basis on which a case or proceeding could have been brought.

**Tampering:** Intentional conduct which subverts the Doping Control process but which would not otherwise be included in the definition of Prohibited Methods. Tampering shall include, without limitation, offering or accepting a bribe to perform or fail to perform an act, preventing the collection of a Sample, affecting or making impossible the analysis of a Sample, falsifying documents submitted to an Anti-Doping Organization or TUE committee or hearing panel, procuring false testimony from witnesses, committing any other fraudulent act upon the Anti-Doping Organization or hearing body to affect
Results Management or the imposition of Consequences, and any other similar intentional interference or Attempted interference with any aspect of Doping Control.

[Comment to Tampering: For example, this Article would prohibit altering identification numbers on a Doping Control form during Testing, breaking the B bottle at the time of “B” Sample analysis, altering a Sample by the addition of a foreign substance, or intimidating or attempting to intimidate a potential witness or a witness who has provided testimony or information in the Doping Control process. Tampering includes misconduct which occurs during the Results Management and hearing process. See Article 10.9.3.3. However, actions taken as part of a Person’s legitimate defense to an anti-doping rule violation charge shall not be considered Tampering. Offensive conduct towards a Doping Control official or other Person involved in Doping Control which does not otherwise constitute Tampering shall be addressed in the disciplinary rules of sport organizations.]

**Target Testing:** Selection of specific Athletes for Testing based on criteria set forth in the International Standard for Testing and Investigations.

**Technical Document:** A document adopted and published by WADA from time to time containing mandatory technical requirements on specific anti-doping topics as set forth in an International Standard.

**Testing:** The parts of the Doping Control process involving test distribution planning, Sample collection, Sample handling, and Sample transport to the laboratory.

**Therapeutic Use Exemption [TUE]:** A Therapeutic Use Exemption allows an Athlete with a medical condition to use a Prohibited Substance or Prohibited Method, but only if the conditions set out in Article 4.4 and the International Standard for Therapeutic Use Exemptions are met.

**Use:** The utilization, application, ingestion, injection or consumption by any means whatsoever of any Prohibited Substance or Prohibited Method.

**WADA:** The World Anti-Doping Agency.

---

### 3.2 Defined Terms from the International Standard for Testing and Investigations

**Doping Control Officer (or DCO):** An official who has been trained and authorized by the Sample Collection Authority to carry out the responsibilities given to DCOs in the International Standard for Testing and Investigations.

**Expert:** The Expert(s) and/or Expert Panel, with knowledge

---

### 3.2 「検査及びドーピング調査に関する国際基準」の定義

【ISTI 定義準用】
in the concerned field, chosen by the Anti-Doping Organization and/or Athlete Passport Management Unit, are responsible for providing an evaluation of the Passport. The Expert must be external to the Anti-Doping Organization.

For the Haematological Module, the Expert panel should consist of at least three (3) Experts who have qualifications in one or more of the fields of clinical and Laboratory haematology, sports medicine or exercise physiology, as they apply to blood doping. For the Steroidal Module, the Expert panel should be composed of at least three (3) individuals with qualifications in the fields of Laboratory steroid analysis, steroid doping and metabolism and/or clinical endocrinology. For both modules, an Expert panel should consist of Experts with complementary knowledge such that all relevant fields are represented. The Expert panel may include a pool of at least three (3) appointed Experts and any additional ad hoc Expert(s) who may be required upon request of any of the appointed Experts or by the Athlete Passport Management Unit of the Anti-Doping Organization.

Sample Collection Authority: The organization that is responsible for the collection of Samples in compliance with the requirements of the International Standard for Testing and Investigations, whether (1) the Testing Authority itself; or (2) a Delegated Third Party to whom the authority to conduct Testing has been granted or sub-contracted. The Testing Authority always remains ultimately responsible under the Code for compliance with the requirements of the International Standard for Testing and Investigations relating to collection of Samples.

Sample Collection Session: All of the sequential activities that directly involve the Athlete from the point that initial contact is made until the Athlete leaves the Doping Control Station after having provided their Sample(s).

Testing Authority: The Anti-Doping Organization that authorizes Testing on Athletes it has authority over. It may authorize a Delegated Third Party to conduct Testing pursuant to the authority of and in accordance with the rules of the Anti-Doping Organization. Such authorization shall be documented. The Anti-Doping Organization authorizing Testing remains the Testing Authority and ultimately responsible under the Code to ensure the Delegated Third Party conducting the Testing does so in compliance with the requirements of the International Standard for Testing and Investigations.

Unsuccessful Attempt Report: A detailed report of an unsuccessful attempt to collect a Sample from an Athlete in a Registered Testing Pool or Testing pool setting out the date of the attempt, the location visited, the exact arrival and departure times at the location, the steps taken at the location to try to find the Athlete (including details of any contact made with third parties), and any other relevant details about the attempt.

Whereabouts Filing: Information provided by or on behalf of an Athlete in a Registered Testing Pool (or Testing pool if
3.3 Defined Terms from the International Standard for Laboratories

Adaptive Model: A mathematical model designed to identify unusual longitudinal results from Athletes. The model calculates the probability of a longitudinal profile of Marker values assuming that the Athlete has a normal physiological condition.

Athlete Passport Management Unit (APMU): A unit composed of a Person or Persons that is responsible for the timely management of Athlete Biological Passports in ADAMS on behalf of the Passport Custodian.

Confirmation Procedure (CP): An Analytical Testing Procedure that has the purpose of confirming the presence and/or, when applicable, confirming the concentration/ratio/score and/or establishing the origin (exogenous or endogenous) of one or more specific Prohibited Substances, Metabolites of a Prohibited Substance, or Marker(s) of the Use of a Prohibited Substance or Prohibited Method in a Sample.

Independent Witness: A Person, invited by the Testing Authority, the Laboratory or WADA to witness parts of the Analytical Testing process. The Independent Witness shall be independent of the Athlete and his/her representative(s), the Laboratory, the Sample Collection Authority, the Testing Authority / Results Management Authority or WADA, as applicable. The Independent Witness may be indemnified for his/her service.

Laboratory(ies): (A) WADA-accredited laboratory(ies) applying Test Methods and processes to provide evidentiary data for the detection and/or identification of Prohibited Substances or Prohibited Methods on the Prohibited List and, if applicable, quantification of a Threshold Substance in Samples of urine and other biological matrices in the context of Doping Control activities.

Laboratory Documentation Package: The material produced by the Laboratory to support an analytical result such as an Adverse Analytical Finding as set forth in the WADA Technical Document for Laboratory Documentation Packages (TD LDOC).

Limit of Quantification (LOQ): Analytical parameter of assay technical performance. Lowest concentration of an Analyte in a Sample that can be quantitatively determined with acceptable precision and accuracy (i.e. acceptable Measurement Uncertainty) under the stated test conditions.

Threshold Substance: An exogenous or endogenous Prohibited Substance, Metabolite or Marker of a Prohibited Substance for which the identification and quantitative determination (e.g. concentration, ratio, score) in excess of a

3.3 「分析機関に関する国際基準」の定義語

「適応モデル」とは、競技者から異常な長期的結果を特定するために設計された数理モデルをいう。このモデルは、競技者が通常の生理上の状態を有している旨推定した上で、マークーの値の長期的プロファイルの確率を算定する。

「アスリート・パスポート・マネジメント・ユニット（APMU）」とは、パスポート保有機関に代わってADAMSにおいてアスリート・バイオロジカル・パスポートの適時管理について責任を負う人により構成されるユニットをいう。

確認分析手続（CP）とは、一つ以上の特定の禁止物質、禁止物質の代謝物、又は検体における禁止物質若しくは禁止方法の使用のマークーの存在を確認し、及び／又は該当する場合には濃度／比率／スコアを確認し、及び／又はその（外因性若しくは内因性の）由来を立証する目的を有する分析検査手続をいう。

独立立会人とは、分析検査手続の一部に立ち会うために検査管轄機関、分析機関又はWADAにより要請される人をいう。独立立会人は、競技者及びその同伴者、分析機関、検体採取機関、検査管轄機関／結果管理機関又はWADA（該当するもの）から独立しているものとする。独立立会人は自己の役務提供のために補償を受ける場合がある。

分析機関とは、禁止表上の禁止物質又は禁止方法の検出及び／又は同定のため、並びに、場合により、ドーピング・コントロール活動の文脈において尿検体その他の生物がマトリックスにおいて関連物質の測定のため証拠となるデータを提供する検査方法及び手続を適用するWADA認定分析機関をいう。

分析機関書類（TD LDOC）のためのWADAテクニカルドキュメントに定めるとおり違法の疑われる分析報告等の分析結果を支持するために分析機関が作成する資料をいう。

定量下限とは、分析の技術的パフォーマンスに関する分析的パラメーターをいう。規定された検査条件の下において許容可能な精度及び正確度（即ち、許容可能な測定の不確かさ）をもって定量的に決定される、検体における分析物の最低濃度をいう。

関連物質とは、外因性又は内因性の禁止物質又は禁止物質の代謝物若しくはマークーであって、それが特定され、事前に定められた判断限界を上回る（例えば、濃度、比率、スコアの）分量が測定された場合に、又
3.4 Defined Term from the International Standard for Therapeutic Use Exemptions

Therapeutic: Of or relating to the treatment of a medical condition by remedial agents or methods; or providing or assisting in a cure.

3.5 Defined Term from the International Standard for Protection of Privacy and Personal Information

Personal Information: Information, including without limitation Sensitive Personal Information, relating to an identified or identifiable Participant or relating to other Person whose information is Processed solely in the context of an Anti-Doping Organization’s Anti-Doping Activities.

[Comment to Personal Information: It is understood that Personal Information includes, but is not limited to, information relating to an Athlete’s name, date of birth, contact details and sporting affiliations, whereabouts, designated TUEs (if any), anti-doping test results, and Results Management (including disciplinary hearings, appeals and sanctions). Personal Information also includes personal details and contact information relating to other Persons, such as medical professionals and other Persons working with, treating or assisting an Athlete in the context of Anti-Doping Activities. Such information remains Personal Information and is regulated by this International Standard for the entire duration of its Processing, irrespective of whether the relevant individual remains involved in organized sport.]

Defined Terms Specific to 3.6 Defined Terms Specific to the International Standard for Results Management

Athlete Biological Passport Documentation Package: The material compiled by the Athlete Passport Management Unit to support an Adverse Passport Finding such as, but not limited to, analytical data, Expert Panel comments, evidence of confounding factors as well as other relevant supporting information.

Expert Panel: The Experts, with knowledge in the concerned field, chosen by the Anti-Doping Organization and/or Athlete Passport Management Unit, who are responsible for providing an evaluation of the Passport. For the Haematological Module, Experts should have knowledge in one or more of the fields of clinical haematology (diagnosis of blood pathological conditions), sports medicine or exercise physiology. For the Steroidal Module, the Experts should have knowledge in Laboratory analysis, steroid
doping and/or endocrinology. For both modules, an Expert Panel should consist of Experts with complementary knowledge such that all relevant fields are represented. The Expert Panel may include a pool of at least three appointed Experts and any additional ad hoc Expert(s) who may be required upon request of any of the appointed Experts or by the Athlete Passport Management Unit of the Anti-Doping Organization.

Failure to Comply: A term used to describe anti-doping rule violations under Code Articles 2.3 and/or 2.5.

Filing Failure: A failure by the Athlete (or by a third party to whom the Athlete has delegated the task) to make an accurate and complete Whereabouts Filing that enables the Athlete to be located for Testing at the times and locations set out in the Whereabouts Filing or to update that Whereabouts Filing where necessary to ensure that it remains accurate and complete, all in accordance with Article 4.8 of the International Standard for Testing and Investigations and Annex B.2 of the International Standard for Results Management.

Hearing Process: The process encompassing the timeframe between the referral of a matter to a hearing panel or tribunal until the issuance and notification of a decision by the hearing panel (whether at first instance or on appeal).

Missed Test: A failure by the Athlete to be available for Testing at the location and time specified in the 60-minute time slot identified in their Whereabouts Filing for the day in question, in accordance with Article 4.8 of the International Standard for Testing and Investigations and Annex B.2 of the International Standard for Results Management.

Passport: A collation of all relevant data unique to an individual Athlete that may include longitudinal profiles of Markers, heterogeneous factors unique to that particular Athlete and other relevant information that may help in the evaluation of Markers.

Passport Custodian: The Anti-Doping Organization responsible for Result Management of the Athlete’s Passport and for sharing any relevant information associated to that Athlete’s Passport with other Anti-Doping Organization(s).

Results Management Authority: The Anti-Doping Organization responsible for conducting Results Management in a given case.

Whereabouts Failure: A Filing Failure or a Missed Test.
<table>
<thead>
<tr>
<th>3.7 Interpretation</th>
<th>3.7 解釈</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7.1 The official text of the <em>International Standard for Results Management</em> shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.</td>
<td>3.7.1 「結果管理に関する国際基準」の正文は、英語及びフランス語で公表されるものとする。英語版とフランス語版との間に矛盾が生じた場合には、英語版が優先するものとする。</td>
</tr>
<tr>
<td>3.7.2 Like the Code, the <em>International Standard for Results Management</em> has been drafted giving consideration to the principles of proportionality, human rights, and other applicable legal principles. It shall be interpreted and applied in that light.</td>
<td>3.7.2 世界規程と同様に、「結果管理に関する国際基準」は、比例性の原則、人権、その他の適用される法的原則を考慮して起草されている。「結果管理に関する国際基準」は、それに照らして解釈され、適用されるものとする。</td>
</tr>
<tr>
<td>3.7.3 The comments annotating various provisions of the <em>International Standard for Results Management</em> shall be used to guide its interpretation.</td>
<td>3.7.3 「結果管理に関する国際基準」の各条項に注釈として付された解説は、本国際基準を解釈するために用いられるものとする。</td>
</tr>
<tr>
<td>3.7.4 Unless otherwise specified, references to Sections and Articles are references to Sections and Articles of the <em>International Standard for Results Management</em>.</td>
<td>3.7.4 別段明示される場合を除き、条項への言及は、いずれもこの「結果管理に関する国際基準」の条項に対する言及である。</td>
</tr>
<tr>
<td>3.7.5 Where the term “days” is used in the <em>International Standard for Results Management</em>, it shall mean calendar days unless otherwise specified.</td>
<td>3.7.5 「結果管理に関する国際基準」に使用されている「日」という用語は、別段明示される場合を除き、暦日をいうものとする。</td>
</tr>
<tr>
<td>3.7.6 The Annexes to the <em>International Standard for Results Management</em> have the same mandatory status as the rest of the <em>International Standard for Results Management</em>.</td>
<td>3.7.6 「結果管理に関する国際基準」の付属文書は、本国際基準のその他の部分と同様に義務的事項である。</td>
</tr>
</tbody>
</table>
PART TWO: RESULTS MANAGEMENT – GENERAL PRINCIPLES

4.0 General Principles

4.1 Confidentiality of Results Management

Save for disclosures, including Public Disclosure, that are required or permitted under Code Article 14 or this International Standard, all processes and procedures related to Results Management are confidential.

4.2 Timeliness

In the interest of fair and effective sport justice, anti-doping rule violations should be prosecuted in a timely manner. Irrespective of the type of anti-doping rule violation involved, and save for cases involving complex issues or delays not in the control of the Anti-Doping Organization (e.g. delays attributable to the Athlete or other Person), Anti-Doping Organizations should be able to conclude Results Management (including the Hearing Process at first instance) within six (6) months from the notification as per Article 5 below.

[Comment to Article 4.2: The six (6) months’ period is a guideline, which may lead to consequences in terms of compliance for the Results Management Authority only in case of severe and/or repeated failure(s).]
PART THREE: RESULTS MANAGEMENT – PRE-ADJUDICATION

5.0 First Results Management Phase

This Article 5 sets out the procedures applicable for the first Results Management phase as follows: Adverse Analytical Findings (Article 5.1), Atypical Findings (Article 5.2) and other matters (Article 5.3), which include potential Failures to Comply (Article 5.3.1.1), Whereabouts Failures (Article 5.3.1.2) and Athlete Biological Passport findings (Article 5.3.1.3). The notification requirements in respect of matters falling under the scope of Article 5.3 are described under Article 5.3.2.

[Comment to Article 5: Where the anti-doping rules of a Major Event Organization provide for an expedited resolution of the limited Results Management, the anti-doping rules of the Major Event Organization may provide that there will be only one notification to the Athlete or other Person. The content of the notification letter should reflect the provisions of Article 5 mutatis mutandis.]

5.1 Adverse Analytical Findings

5.1.1 Initial Review

Upon receipt of an Adverse Analytical Finding, the Results Management Authority shall conduct a review to determine whether (a) an applicable TUE has been granted or will be granted as provided in the International Standard for Therapeutic Use Exemptions (Article 5.1.1.1), (b) there is any apparent departure from the International Standard for Testing and Investigations or International Standard for Laboratories that caused the Adverse Analytical Finding (Article 5.1.1.2) and/or (c) it is apparent that the Adverse Analytical Finding was caused by an ingestion of the relevant Prohibited Substance through a permitted route (Article 5.1.1.3).

5.1.1.1 Therapeutic Use Exemption

5.1.1.1.1 The Results Management Authority shall consult the Athlete’s records in ADAMS and other Anti-Doping Organizations that might have approved a TUE for the Athlete (e.g., the National Anti-Doping Organization or the International Federation) to determine whether a TUE exists.

[Comment to Article 5.1.1.1: As per the Prohibited List and the TD DL, the detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of certain Threshold Substances (identified in the Prohibited List), in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent. Therefore, in the Event of such detection, the Results Management Authority shall also determine whether the

第3部 結果管理・裁前

5.0 結果管理の第一段階

この第5条は、以下のとおり、結果管理の第一段階に適用される手続きを定める。違反が疑われる分析報告（第5.1項）、非定型報告（第5.2項）、並びに、不遵守（第5.3.1.1項）、場所情報関連義務違反（第5.3.1.2項）及びアスリート・バイオロジカル・パスポートに基づく違反が疑われる報告（第5.3.1.3項）を含む他の事項（第5.3項）。また、第5.3項の範囲に該当する事項に関連する通知要件は第5.3.2項に記述されている。

[第5項の解説：主要競技大会機関のアンチ・ドーピング規則が限定された結果管理の迅速な解決について定める場合には、主要競技大会機関のアンチ・ドーピング規則は、競技者又はその他の人に対し1回のみ通知を行うことを定める場合がある。通知レターの内容は、第5条の条項に準じて作成されるべきである。]

5.1 違反が疑われる分析報告

5.1.1 初期審査

結果管理機関は、違反が疑われる分析報告を受領するにあたり、(a)「治療使用特例に関する国際基準」に定めるとおり適用されるTUEが付与され又は今後付与されるか否か（第5.1.1.1項）、(b)違反が疑われる分析報告の原因となった「検査及びドーピング調査に関する国際基準」又は「分析機関に関する国際基準」からの明白な乖離があったか否か及び/又は(c)違反が疑われる分析報告が、認められた経路を通じた関連する禁止物質の摂取に起因することが明白であるか否かを判断するために審査を行うものとする。

5.1.1.1 治療使用特例

5.1.1.1.1 結果管理機関は、TUEが存在するか否かを判断するために、ADAMS及び競技者のためのTUEを承認した可能性のある他のアンチ・ドーピング機関（例えば、国内アンチ・ドーピング機関又は国際競技連盟）における競技者の記録を参照するものとする。

[第5.1.1.1項の解説：禁止表及びTD DLに従い、利尿薬又は隠蔽薬と一緒に、（禁止表で特定される）特定の閾値物質が分量を問わず、いつでも又は競技会中（時）に競技者の検体から検出された場合には、競技者が利尿薬又は隠蔽薬のために付与されたTUEに加え、当該物質について承認されたTUEを有している場合を除き、これは違反が疑われる分析報告であるとみなされる。よって、このような検出があった場合には、結果管理機関は、当該競技者が、検出された閾値物質について承認されたTUEを有しているか否かについても]
5.1.1.1.2 If the initial review reveals that the **Athlete** has an applicable **TUE** for the detected **Threshold Substance**, then the **Results Management Authority** shall conduct such follow up review as necessary to determine if the specific requirements of the **TUE** have been complied with.

5.1.1.2 **Apparent Departure from International Standard for Testing and Investigations and/or International Standard for Laboratories**

The **Results Management Authority** must review the **Adverse Analytical Finding** to determine if there has been any departure from the **International Standard for Testing and Investigations** and/or the **International Standard for Laboratories**. This may include a review of the Laboratory **Documentation Package** produced by the **Laboratory** to support the **Adverse Analytical Finding** (if available at the time of the review) and relevant **Doping Control** form(s) and **Testing documents**.

5.1.1.3 **Apparent Ingestion through Permitted Route**

If the **Adverse Analytical Finding** involves a **Prohibited Substance** permitted through (a) specific route(s) as per the **Prohibited List**, the **Results Management Authority** shall consult any relevant available documentation (e.g. **Doping Control form**) to determine whether the **Prohibited Substance** appears to have been administered through a permitted route and, if so, shall consult an expert to determine whether the **Adverse Analytical Finding** is compatible with the apparent route of ingestion.

[Comment to Article 5.1.1.3: For the sake of clarity, the outcome of the initial review shall not prevent an **Athlete** from arguing that his Use of the **Prohibited Substance** came from a permitted route at a later stage of Results Management.]

5.1.2 **Notification**

5.1.2.1 If the review of the **Adverse Analytical Finding** does not reveal an applicable **TUE** or entitlement to the same as provided in the **International Standard for Therapeutic Use Exemptions**, a departure from the **International Standard for Testing and Investigations** or the **International Standard for Laboratories** that caused the **Adverse Analytical Finding** or that it is apparent that the **Adverse Analytical Finding** was caused by an ingestion of the relevant **Prohibited Substance** through an authorized route, the **Results Management Authority** shall promptly notify the **Athlete** of:

a) The **Adverse Analytical Finding**;

[Comment to Article 5.1.2.1 a): In the event that the **Adverse Analytical Finding** relates to salbutamol, formoterol, human chorionic gonadotrophin or another...]

5.1.2.2 「検査及びドーピング調査に関する国際基準」及び/又は「分析機関に関する国際基準」からの明白な乖離

結果管理機関は、「検査及びドーピング調査に関する国際基準」及び/又は「分析機関に関する国際基準」からの乖離が存在するか否かを判断するために、違反が疑われる分析報告を審査しなければならない。これは、違反が疑われる分析報告を裏付けるため、分析機関によって作成された分析機関書類（審査時に利用可能な場合）並びに関連するドーピング・コントロール・フォーム及び検査文書の審査を含む場合がある。

5.1.3 **認められた経路を通じた明白な摂取**

違反が疑われる分析報告が、禁止表に従い、特定の経路を通じて許可される禁止物質に関連する場合には、結果管理機関は、当該禁止物質が認められた経路を通じて投与されたものとみられるか判断するために、関連する入手可能な文書（例えば、ドーピング・コントロール・フォーム）を参照し、また、そのようにみられる場合には、違反が疑われる分析報告が明白な摂取経路と両立可能であるか否かを判断するために専門家に相談するものとする。

[第5.1.3項の解説：明確化のために付言すると、初期審査の結果は、競技者が、自己の禁止物質の使用が認められた経路に由来するものであることを、結果管理の後の段階で主張することを妨げないものとする。]

5.1.2 通知

5.1.2.1 違反が疑われる分析報告のレビューの結果、『治療使用特例に関する国際基準』に定めるとおり、適用されるTUE若しくは適用されるTUEへの権利、又は、違反が疑われる分析報告の原因となった『検査及びドーピング調査に関する国際基準』若しくは『分析機関に関する国際基準』からの乖離が判明しなかった場合、又は、違反が疑われる分析報告が、承認された経路を通じた関連禁止物質の摂取に起因することが明白な場合には、結果管理機関は競技者に以下の事項を速やかに通知するものとする。

a) 違反が疑われる分析報告

[第5.1.2.1項の解説：違反が疑われる分析報告がサルブタモール、ホルモドロール、ヒト総合性ゴナドトロピン又はテクニカルドキュメントにおいて特定の結...]

a) **The Adverse Analytical Finding**;
Prohibited Substance subject to specific Results Management requirements in a Technical Document, the Results Management Authority shall in addition comply with Article 5.1.2.2. The Athlete shall be provided with any relevant documentation, including a copy of the Doping Control form and the Laboratory results.

b) The fact that the Adverse Analytical Finding may result in an anti-doping rule violation of Code Article 2.1 and/or Article 2.2 and the applicable Consequences;

[Comment to Article 5.1.2.1 b): The Results Management Authority should always refer to both Code Articles 2.1 and 2.2 in the notification and charge letter (Article 7) to an Athlete if the matter relates to an Adverse Analytical Finding. The Results Management Authority shall refer to ADAMS and contact WADA and other relevant Anti-Doping Organizations to determine whether any prior anti-doping rule violation exists and take such information into account in determining the applicable Consequences.]

c) The Athlete’s right to request the analysis of the “B” Sample or, failing such request, that the “B” Sample analysis may be deemed irrevocably waived;

[Comment to Article 5.1.2.1 c): The Results Management Authority may still request the “B” Sample analysis even if the Athlete does not request the “B” Sample analysis or expressly or impliedly waives their right to analysis of the “B” Sample. The Results Management Authority may provide in its anti-doping rules that the costs of the “B” Sample analysis shall be covered by the Athlete.]

d) The opportunity for the Athlete and/or the Athlete’s representative to attend the “B” Sample opening and analysis in accordance with the International Standard for Laboratories;

e) The Athlete’s right to request copies of the “A” Sample Laboratory Documentation Package which includes information as required by the International Standard for Laboratories;

[Comment to Article 5.1.2.1 e): This request shall be made to the Results Management Authority and not the Laboratory directly. The Results Management Authority may provide in its anti-doping rules that the costs relating to the issuance of the Laboratory Documentation Package(s) shall be covered by the Athlete.]

f) The opportunity for the Athlete to provide an explanation within a short deadline;

g) The opportunity for the Athlete to provide Substantial Assistance as set out under Code Article 10.7.1, to admit the anti-doping rule violation and potentially benefit from a one-year reduction in the period of Ineligibility under Code Article 10.8.1 (if applicable) or to seek to enter into a case
resolution agreement under Code Article 10.8.2; and

h) Any matters relating to Provisional Suspension (including the possibility for the Athlete to accept a voluntary Provisional Suspension) as per Article 6 (if applicable).

5.1.2.2 In addition, in the event that the Adverse Analytical Finding relates to the Prohibited Substances set out below, the Results Management Authority shall:

a) Salbutamol or Formoterol: draw the attention of the Athlete in the notification letter that the Athlete can prove, through a controlled pharmacokinetic study, that the Adverse Analytical Finding was the consequence of a Therapeutic dose by inhalation up to the maximum dose indicated under class S3 of the Prohibited List. The Athlete’s attention shall in addition be drawn to the key guiding principles for a controlled pharmacokinetic study and they shall be provided with a list of Laboratories, which could perform the controlled pharmacokinetic study. The Athlete shall be granted a deadline of seven (7) days to indicate whether they intend to undertake a controlled pharmacokinetic study, failing which the Results Management Authority may proceed with the Results Management;

b) Urinary human chorionic gonadotrophin: follow the procedures set out at Article 6 of the TD2019CG/LH or any subsequent version of the Technical Document;

c) Other Prohibited Substance subject to specific Results Management requirements in a Technical Document or other document issued by WADA: follow the procedures set out in the relevant Technical Document or other document issued by WADA.

5.1.2.3 The Results Management Authority shall also indicate the scheduled date, time and place for the “B” Sample analysis for the eventuality that the Athlete or Results Management Authority chooses to request an analysis of the “B” Sample; it shall do so either in the notification letter described in Article 5.1.2.1 or in a subsequent letter promptly after the Athlete (or the Results Management Authority) has requested the “B” Sample analysis.

[Comment to Article 5.1.2.3: As per Article 5.3.4.5.4.8.5 of the International Standard for Laboratories, the “B” Sample confirmation should be performed as soon as possible, and no later than three (3) months, following the reporting of the “A” Sample Adverse Analytical Finding.

The timing of the “B” Sample confirmation analysis may be strictly fixed in the short term with no postponement possible, when circumstances so justify it. This can notably and without limitation be the case in the context of Testing during or immediately before or after Major Events, or when the further postponement of the “B” Sample analysis

1) [第5.1.2.3 項の解説：「分析機関に関する国際基準」の第5.3.4.5.4.8.5 項に従い、「B」検体の分析の要請することを選択した場合のために、「B」検体の分析のために予定された日、時間及び場所を示すものとする。結果管理機関は、第5.1.2.1 項に記載する通知レターにおいて、も又、競技者（又は結果管理機関）が「B」検体の分析を要請した後速やかに後続のレターにおいて、これを行うものとする。]

【第5.1.2.3 項の解説：「分析機関に関する国際基準」の第5.3.4.5.4.8.5 項に従い、「B」検体の確認は、「A」検体の違反が疑われる分析報告が報告されてから少なくとも 3 ヶ月以内に、可及的速やかに行われるべきである。】

「B」検体の確認の時期は、状況がそれを正当化する場合には、延期の可能性なく、短期間で厳格に確定される場合がある。これは、主要競技大会中若しくはその直前若しくは直後の検査の文脈において、又は「B」検体の分析の更なる延期が検体の劣化のリスクの重大な増加を生じさせる場合には、特にあてはまりうるが、
could significantly increase the risk of Sample degradation."

5.1.2.4 If the Athlete requests the “B” Sample analysis but claims that they and/or their representative is not available on the scheduled date indicated by the Results Management Authority, the Results Management Authority shall liaise with the Laboratory and propose (at least) two (2) alternative dates.

[Comment to Article 5.1.2.4: The alternative dates should take into account: (1) the reasons for the Athlete’s unavailability; and (2) the need to avoid any degradation of the Sample and ensure timely Results Management.]

5.1.2.5 If the Athlete and their representative claim not to be available on the alternative dates proposed, the Results Management Authority shall instruct the Laboratory to proceed regardless and appoint an Independent Witness to verify that the “B” Sample container shows no signs of Tampering and that the identifying numbers match that on the collection documentation.

[Comment to Article 5.1.2.5: An Independent Witness may be appointed even if the Athlete has indicated that they will be present and/or represented.]

5.1.2.6 If the results of the “B” Sample analysis confirm the results of the “A” Sample analysis, the Results Management Authority shall promptly notify the Athlete of such results and shall grant the Athlete a short deadline to provide or supplement their explanations. The Athlete shall also be afforded the possibility to admit the anti-doping rule violation to potentially benefit from a one-year reduction in the period of Ineligibility under Code Article 10.8.1, if applicable, and/or to voluntarily accept a Provisional Suspension as per Code Article 7.4.4.

5.1.2.7 Upon receipt of any explanation from an Athlete, the Results Management Authority may, without limitation, request further information and/or documents from the Athlete within a set deadline or liaise with third parties in order to assess the validity of the explanation.

[Comment to Article 5.1.2.7: If the positive finding involves a Prohibited Substance subject to a permitted route (e.g. by inhalation, by transdermal or by ophthalmic Use) and the Athlete alleged that the positive finding came from the permitted route, the Results Management Authority should assess the credibility of the explanation by contacting third parties (including scientific experts) before deciding not to move forward with Results Management.]

5.1.2.8 Any communication provided to the Athlete under this Article 5.1.2 shall simultaneously be provided by the Results Management Authority to the Athlete’s National Anti-Doping Organization(s), International Federation and WADA and shall promptly be reported into ADAMS.

5.1.2.4 競技者が「B」検体の分析を要請するが、自己及び／又はその同伴者が結果管理機関が示す予定日に応じることができない旨主張する場合には、結果管理機関は、分析機関と連携して(少なくとも)2つの代替日を提案するものとする。

[第5.1.2.4項の解説:代替日は、(1)競技者が応じることができない理由、及び(2)検体の劣化を回避し、適時の結果管理を確保する必要性を考慮に入れるべきである。]

5.1.2.5 競技者及びその同伴者が提案された代替日に応じることができない旨主張する場合には、結果管理機関は、分析機関に対し、これにかまわず手続を進めること、及び、「B」検体の容器が不正干渉の徴候を示さず、識別番号が検体採取文書の番号と一致することを検証するために、独立立会人を任命するよう指示するものとする。

[第5.1.2.5項の解説: 独立立会人は、競技者が、自己が出席し及び／又は代理される意向を表明したとしても任命される場合がある。]

5.1.2.6 「B」検体の分析の結果、「A」検体の分析の結果が確認された場合には、結果管理機関は、当該結果について速やかに競技者に通知するものとし、競技者に対し自己の弁明を提供し又は補充するよう短期の期限を付与するものとする。また、競技者は、該当する場合には、世界規程第10.8.1項に基づく資格停止期間の1年間の短縮（該当する場合）から利益を受けるべく、アンチ・ドーピング規則違反を自認し、及び／又は、世界規程第7.4.4項に従い暫定的資格停止期間を任意で受諾する可能性を与えられるものとする。

5.1.2.7 競技者から弁明を受けるにあたり、結果管理機関は、特定の期限内に競技者からの更なる情報及び／又は文書を要求し、弁明の妥当性を評価するために第三者と共連携することができるが、これに限らない。

(第5.1.2.7項の解説:陽性結果が、認められた経路(例えば、吸気、吸皮又は眼科使用により)の対象となる禁止物質に関連し、競技者が当該陽性結果が認められた経路に由来するものである旨主張した場合には、結果管理機関は、結果管理を進行させない旨決定する前に、第三者（科学専門家を含む。）に連絡を取ることにより当該弁明の信用性を評価すべきである。]

5.1.2.8 この第5.1.2項に基づき競技者に提供された伝達事項は、結果管理機関から競技者の国内アンチ・ドーピング機関、国際競技連盟及びWADAにともに提供されるものとし、速やかにADAMSに報告されるものとする。
5.2 Atypical Findings

5.2.1 Upon receipt of an Atypical Finding, the Results Management Authority shall conduct a review to determine whether: (a) an applicable TUE has been granted or will be granted as provided in the International Standard for Therapeutic Use Exemptions (see Article 5.1.1 by analogy); (b) there is any apparent departure from the International Standard for Testing and Investigations or International Standard for Laboratories that caused the Atypical Finding (see Article 5.1.2 by analogy) and/or (c) it is apparent that the ingestion of the Prohibited Substance was through a permitted route (see Article 5.1.3 by analogy). If that review does not reveal an applicable TUE apparent departure that caused the Atypical Finding or an ingestion through a permitted route, the Results Management Authority shall conduct the required investigation.

[Comment to Article 5.2.1: If the Prohibited Substance involved is subject to specific Results Management requirements in a Technical Document, the Results Management Authority shall also follow the procedures set out therein.]

5.2.2 The Results Management Authority need not provide notice of an Atypical Finding until it has completed its investigation and decided whether it will bring the Atypical Finding forward as an Adverse Analytical Finding unless one of the following circumstances exists:

a) If the Results Management Authority determines that the “B” Sample should be analyzed prior to the conclusion of its investigation, the Results Management Authority may conduct the “B” Sample analysis after notifying the Athlete, with such notice to include a description of the Atypical Finding and the information described in Article 5.1.2.1 c) to e) and Article 5.1.2.3;

b) If the Results Management Authority receives a request, either from a Major Event Organization shortly before one of its International Events or from a sport organization responsible for meeting an imminent deadline for selecting

[Comment to Article 5.1.2.8: To the extent not already set out in the communication to the Athlete, this notification shall include the following information (if applicable): the Athlete’s name, country, sport and discipline within the sport, whether the test was In-Competition or Out-of-Competition, the date of Sample collection, the analytical result reported by the Laboratory and other information as required by the International Standard for Testing and Investigations.]
team members for an International Event, to disclose whether any Athlete identified on a list provided by the Major Event Organization or sport organization has a pending Atypical Finding, the Results Management Authority shall identify any Athlete after first providing notice of the Atypical Finding to the Athlete; or

c) If the Atypical Finding is, in the opinion of qualified medical or expert personnel, likely to be connected to a serious pathology that requires urgent medical attention.

5.2.3 If after the investigation is completed the Results Management Authority decides to pursue the Atypical Finding as an Adverse Analytical Finding, then the procedure shall follow the provisions of Article 5.1 mutatis mutandis.

5.3 Matters not Involving an Adverse Analytical Finding or Atypical Finding

5.3.1 Specific cases

5.3.1.1 Report of a potential Failure to Comply

The pre-adjudication phase of Results Management of a possible Failure to Comply shall take place as provided in Annex A – Review of a Possible Failure to Comply.

5.3.1.2 Whereabouts Failures

The pre-adjudication phase of Results Management of potential Whereabouts Failures shall take place as provided in Annex B – Results Management for Whereabouts Failures.

5.3.1.3 Athlete Biological Passport Findings

The pre-adjudication phase of Results Management of Atypical Passport Findings or Passports submitted to an Expert by the Athlete Passport Management Unit when there is no Atypical Passport Finding shall take place as provided in Annex C – Results Management Requirements and Procedures for the Athlete Biological Passport.

5.3.2 Notification for specific cases and other anti-doping rule violations under Article 5.3

5.3.2.1 At such time as the Results Management Authority considers that the Athlete or other Person may have committed (an) anti-doping rule violation(s), the Results Management Authority shall promptly notify the Athlete of:

a) The relevant anti-doping rule violation(s) and the applicable Consequences;

b) The relevant factual circumstances upon which the allegations are based;

c) The relevant evidence in support of those facts that the
Results Management Authority considers demonstrate that the Athlete or other Person may have committed (an) anti-doping rule violation(s);

d) The Athlete or other Person’s right to provide an explanation within a reasonable deadline;

e) The opportunity for the Athlete or other Person to provide Substantial Assistance as set out in Code Article 10.7.1, to admit the anti-doping rule violation and potentially benefit from a one-year reduction in the period of Ineligibility in Code Article 10.8.1 (if applicable) or seek to enter into a case resolution agreement in Code Article 10.8.2; and

f) Any matters relating to Provisional Suspension (including the possibility for the Athlete or other Person to accept a voluntary Provisional Suspension) as per Article 6 (if applicable).

5.3.2.2 Upon receipt of the Athlete’s or other Person’s explanation, the Results Management Authority may, without limitation, request further information and/or documents from the Athlete or other Person within a set deadline or liaise with third parties in order to assess the validity of the explanation.

5.3.2.3 The communication provided to the Athlete or other Person shall simultaneously be provided by the Results Management Authority to the Athlete’s or other Person’s National Anti-Doping Organization(s), International Federation and WADA and shall promptly be reported into ADAMS.

[Comment to Article 5.3.2.3: To the extent not already set out in the communication to the Athlete or other Person, this notification shall include the following information (if applicable): the Athlete’s or other Person’s name, country, sport and discipline within the sport.]

5.4 Decision Not to Move Forward

If at any point during Results Management up until the charge under Article 7, the Results Management Authority decides not to move forward with a matter, it must notify the Athlete or other Person (provided that the Athlete or other Person had been already informed of the ongoing Results Management) and give notice (with reasons) to the Anti-Doping Organizations with a right of appeal under Code Article 13.2.3.
6.0 Provisional Suspensions

6.1 Scope

6.1.1 In principle, a Provisional Suspension means that an Athlete or other Person is barred temporarily from participating in any capacity in any Competition or activity as per Code Article 10.14.1 prior to the final decision at a hearing pursuant to Article 8.

6.1.2 Where the Results Management Authority is the ruling body of an Event or is responsible for team selection, the rules of such Results Management Authority shall provide that the Provisional Suspension is limited to the scope of the Event, respectively team selection. Upon notification under Article 5, the International Federation of the Athlete or other Person shall be responsible for Provisional Suspension beyond the scope of the Event.

6.2 Imposition of a Provisional Suspension

6.2.1 Mandatory Provisional Suspension

6.2.1.1 As per Code Article 7.4.1, Signatories identified in the provision shall adopt rules providing that when an Adverse Analytical Finding or Adverse Passport Finding (upon completion of the Adverse Passport Finding review process) is received for a Prohibited Substance or a Prohibited Method other than a Specified Substance or Specified Method, a Provisional Suspension shall be imposed promptly upon or after the review and notification required by Code Article 7.2.

[Comment to Article 6.2.1.1: The review and notification required by Code Article 7.2 is set out in Article 5.]

6.2.1.2 A mandatory Provisional Suspension may be eliminated if: (i) the Athlete demonstrates to the hearing panel that the violation is likely to have involved a Contaminated Product, or (ii) the violation involves a Substance of Abuse and the Athlete establishes entitlement to a reduced period of Ineligibility under Code Article 10.2.4.1. A hearing body’s decision not to eliminate a mandatory Provisional Suspension on account of the Athlete’s assertion regarding a Contaminated Product shall not be appealable.

6.2.2 Optional Provisional Suspension

As per Code Article 7.4.2, a Signatory may adopt rules, applicable to any Event for which the Signatory is the ruling body or to any team selection process for which the Signatory is responsible or where the Signatory is the applicable International Federation or has Results Management Authority over the alleged anti-doping rule violation, permitting Provisional Suspensions to be imposed for anti-doping rule violations not covered by Code Article 7.4.1 prior to analysis of the Athlete’s “B” Sample or final hearing as described in Code Article 8. The
optional *Provisional Suspension* may also be lifted at the discretion of the *Results Management Authority* at any time prior to the hearing panel decision under Article 8, unless provided otherwise.

[Comment to Article 6.2.2: Whether or not to impose an optional *Provisional Suspension* is a matter for the *Results Management Authority* to decide in its discretion, taking into account all the facts and evidence. The *Results Management Authority* should keep in mind that if an Athlete continues to compete after being notified and/or charged in respect of an anti-doping rule violation and is subsequently found to have committed an anti-doping rule violation, any results, prizes and titles achieved and awarded in that timeframe may be subject to *Disqualification* and forfeited.

Nothing in this provision prevents provisional measures (including a lifting of the *Provisional Suspension* upon request of the Athlete or other Person) being ordered by the hearing panel.]

6.2.3 General Provisions

6.2.3.1 Notwithstanding Articles 6.2.1 and 6.2.2, a *Provisional Suspension* may not be imposed unless the rules of the *Anti-Doping Organization* provide the *Athlete* or other *Person* with: (a) an opportunity for a *Provisional Hearing*, either before imposition of the *Provisional Suspension* or on a timely basis after imposition of the *Provisional Suspension*; or (b) an opportunity for an expedited hearing in accordance with *Code* Article 8 on a timely basis after imposition of a *Provisional Suspension*. The rules of the *Anti-Doping Organization* shall also provide for an opportunity for an expedited appeal against the imposition of a *Provisional Suspension*, or the decision not to impose a *Provisional Suspension*, in accordance with *Code* Article 13.

6.2.3.2 A *Provisional Suspension* shall start on the date on which it is notified (or deemed to be notified) by the *Results Management Authority* to the *Athlete* or other *Person*.

6.2.3.3 The period of *Provisional Suspension* shall end with the final decision of the hearing panel conducted under Article 8, unless earlier lifted in accordance with this Article 6. However, the period of *Provisional Suspension* shall not exceed the maximum length of the period of *Ineligibility* that may be imposed on the *Athlete* or other *Person* based on the relevant anti-doping rule violation(s).

6.2.3.4 If a *Provisional Suspension* is imposed based on an “A” *Sample Adverse Analytical Finding* and a subsequent “B” *Sample analysis* does not confirm the “A” *Sample analysis* result, then the *Athlete* shall not be subject to any further *Provisional Suspension* on account of a violation of *Code* Article 2.1.

[Comment to Article 6.2.3.4: The *Results Management Authority* may nonetheless decide to maintain and/or...]

6.2.3.1 第 6.2.1 項及び第 6.2.2 項にかかわらず、アンチ・ドーピング機関の規則が競技者又はその他の人に以下を提供する場合を除き、暫定的資格停止は賦課されない。以上の暫定的資格停止の賦課前、又は暫定的資格停止の賦課後適時に暫定聴聞会機会、又は(b) 暫定的資格停止の賦課後において適時に世界規程第 8 条に従った緊急の聴聞を受ける機会。また、アンチ・ドーピング機関の規則は、世界規程第 13 条に従い暫定的資格停止の賦課、又は暫定的資格停止を賦課しない旨の決定に対する簡易な不服申立ての機会を定めるものとする。

6.2.3.2 暫定的資格停止は、それが結果管理機関により競技者又はその他の人に通知された日（又は通知されたとみなされた日）から開始するものとする。

6.2.3.3 暫定的資格停止期間は、本国際基準第 6 条に従い先に解除された場合を除き、第 8 条に基づき行われた聴聞パネルの終局的な決定により終了するものとする。しかし、暫定的資格停止期間は、関連するアンチ・ドーピング規則違反に基づき競技者又はその他の人に賦課されるべき資格停止期間の最長期間を超えないものとする。

6.2.3.4 「A」検体の違反が疑われる分析報告に基づき暫定的資格停止が賦課されたが、それに続く「B」検体の分析が「A」検体の分析結果を追認しない場合には、競技者は、世界規程第 2.1 項の違法を理由としてそれ以上の暫定的資格停止は賦課されないものとする。

[第 6.2.3.4 項の解説：それにもかかわらず、結果管理機関は、競技者に通知された別のアンチ・ドーピング...]

26
re-impose a Provisional Suspension on the Athlete based on another anti-doping rule violation notified to the Athlete, e.g. a violation of Code Article 2.2.]

6.2.3.5 In circumstances where the Athlete (or the Athlete’s team as may be provided in the rules of the applicable Major Event Organization or International Federation) has been removed from an Event based on a violation of Code Article 2.1 and the subsequent “B” Sample analysis does not confirm the “A” Sample finding, if, without otherwise affecting the Event, it is still possible for the Athlete or team to be reinstated, the Athlete or team may continue to take part in the Event.

6.3 Voluntary Provisional Suspension

6.3.1 As per Code Article 7.4.4, Athletes on their own initiative may voluntarily accept a Provisional Suspension if done so prior to the later of: (i) the expiration of ten (10) days from the report of the “B” Sample (or waiver of the “B” Sample) or ten (10) days from notification of any other anti-doping rule violation, or (ii) the date on which the Athlete first competes after such report or notification. Other Persons on their own initiative may voluntarily accept a Provisional Suspension if done so within ten (10) days from notification of the anti-doping rule violation. Upon such voluntary acceptance, the Provisional Suspension shall have the full effect and be treated in the same manner as if the Provisional Suspension had been imposed under Article 6.2.1 or 6.2.2; provided, however, at any time after voluntarily accepting a Provisional Suspension, the Athlete or other Person may withdraw such acceptance, in which event the Athlete or other Person shall not receive any credit for time previously served during the Provisional Suspension.

6.4 Notification

6.4.1 Unless already notified under another provision of this International Standard, any imposition of a Provisional Suspension notified to the Athlete or other Person or voluntary acceptance of a Provisional Suspension, or lifting of either, shall promptly be notified by the Results Management Authority to the Athlete’s or other Person’s National Anti-Doping Organization(s), International Federation and WADA and shall promptly be reported into ADAMS.

[Comment to Article 6.4.1: To the extent not already set out in the communication to the Athlete, this notification shall include the following information (if applicable): the Athlete’s or other Person’s name, country, sport and discipline within the sport.]
7.0 Charge

7.1 If, after receipt of the Athlete or other Person’s explanation or expiry of the deadline to provide such explanation, the Results Management Authority is (still) satisfied that the Athlete or other Person has committed (an) anti-doping rule violation(s), the Results Management Authority shall promptly charge the Athlete or other Person with the anti-doping rule violation(s) they are asserted to have breached. In this letter of charge, the Results Management Authority:

a) Shall set out the provision(s) of its anti-doping rules asserted to have been violated by the Athlete or other Person;

[Comment to Article 7.1 a): The Results Management Authority is not limited by the anti-doping rules violation(s) set out in the notification under Article 5. In its discretion, the Results Management Authority may decide to assert further anti-doping rule violation(s) in its notice of charge. Notwithstanding the above, whereas it is a Results Management Authority’s duty to set out all and any asserted anti-doping rule violations against an Athlete or other Person in the notice of charge, a failure to formally charge an Athlete with an anti-doping rule violation that is in principle an integral part of a more specific (asserted) anti-doping rule violation (e.g. a Use violation (Code Article 2.2) as part of a Presence violation (Code Article 2.1), or a Possession violation (Code Article 2.6) as part of an asserted Administration violation (Code Article 2.8)) shall not prevent a hearing panel from finding that the Athlete or other Person committed a violation of the subsidiary anti-doping rule violation in the event that they are not found to have committed the explicitly asserted anti-doping rule violation.]

b) Shall provide a detailed summary of the relevant facts upon which the assertion is based, enclosing any additional underlying evidence not already provided in the notification under Article 5;

[Comment to Article 7.1 b): The Results Management Authority shall, however, not be prevented from relying on other facts and/or adducing further evidence not contained in either the notification letter under Article 5 or the charge letter under Article 7 during the Hearing Process at first instance and/or on appeal.]

c) Shall indicate the specific Consequences being sought in the event that the asserted anti-doping rule violation(s) is/are upheld and that such Consequences shall have binding effect on all Signatories in all sports and countries as per Code Article 15;

[Comment to Article 7.1 c): The Consequences of an anti-doping rule violation set out in the letter of charge shall include as a minimum the relevant period of Ineligibility and Disqualification. The Results Management Authority shall refer to ADAMS and contact WADA and other relevant]
Anti-Doping Organizations to determine whether any prior anti-doping rule violation exists and take such information into account in determining the relevant Consequences. The proposed Consequences shall in all circumstances be compatible with the provisions of the Code and shall be appropriate based on the explanations given by the Athlete or other Person or the facts as established by the Results Management Authority. For these purposes, it is expected that the Results Management Authority will review the explanations given by the Athlete or other Person and assess their credibility (for example, by checking the authenticity of documentary evidence and the plausibility of the explanation from a scientific perspective) before proposing any Consequences. If the Results Management phase is substantially delayed by the review, the Results Management Authority shall inform WADA, setting out the reasons for the substantial delay.

d) Shall grant a deadline of not more than twenty (20) days from receipt of the letter of charge (which may be extended only in exceptional cases) to the Athlete or other Person to admit the anti-doping rule violation asserted and to accept the proposed Consequences by signing, dating and returning an acceptance of Consequences form, which shall be enclosed to the letter;

e) For the eventuality that the Athlete or other Person does not accept the proposed Consequences, shall already grant to the Athlete or other Person a deadline provided for in the Results Management Authority’s anti-doping rules (which shall not be of more than twenty (20) days from receipt of the letter of charge and may be extended only in exceptional cases) to challenge in writing the Results Management Authority’s assertion of an anti-doping rule violation and/or proposed Consequences, and/or make a written request for a hearing before the relevant hearing panel;

f) Shall indicate that if the Athlete or other Person does not challenge the Results Management Authority’s assertion of an anti-doping rule violation or proposed Consequences nor request a hearing within the prescribed deadline, the Results Management Authority shall be entitled to deem that the Athlete or other Person has waived their right to a hearing and admitted the anti-doping rule violation as well as accepted the Consequences set out by the Results Management Authority in the letter of charge;

g) Shall indicate that the Athlete or other Person may be able to obtain a suspension of Consequences if they provide Substantial Assistance under Code Article 10.7.1, may admit the anti-doping rule violation(s) within twenty (20) days from receipt of the letter of charge and potentially benefit from a one-year reduction in the period of Ineligibility under Code Article 10.8.1 (if applicable) and/or seek to enter into a case resolution agreement by admitting the anti-doping rule violation(s) under Code Article 10.8.2; and

h) Shall set out any matters relating to Provisional Suspension as per Article 6 (if applicable).
The notice of charge notified to the Athlete or other Person shall simultaneously be notified by the Results Management Authority to the Athlete’s National Anti-Doping Organization(s), International Federation and WADA and shall promptly be reported into ADAMS.

[Comment to Article 7.2: To the extent not already set out in the notice of charge, this notification shall contain the following information (wherever applicable): Athlete’s or other Person’s name, country, sport and discipline within the sport, and, for any other anti-doping rule violation, the anti-doping rule(s) violated and the basis for the asserted violation(s).]

In the event that the Athlete or other Person either (i) admits the anti-doping rule violation and accepts the proposed Consequences or (ii) is deemed to have admitted the violation and accepted the Consequences as per Article 7.1 f), the Results Management Authority shall promptly issue the decision and notify it in accordance with Article 9.

If, after the Athlete or other Person has been charged, the Results Management Authority decides to withdraw the charge, it must notify the Athlete or other Person and give notice (with reasons) to the Anti-Doping Organizations with a right of appeal under Code Article 13.2.3.

Subject to Article 7.6, in the event that the Athlete or other Person requests a hearing, the matter shall be referred to the Results Management Authority’s hearing panel and be dealt with pursuant to Article 8.

[Comment to Article 7.5: Where a Results Management Authority has delegated the adjudication part of Results Management to a Delegated Third Party, the matter shall be referred to the Delegated Third Party.]

Single hearing before CAS

Pursuant to Code Article 8.5, anti-doping rule violations asserted against International-Level Athletes, National-Level Athletes or other Persons may, with the consent of the Athlete or other Person, the Results Management Authority and WADA, be heard in a single hearing directly at CAS under CAS appellate procedures, with no requirement for a prior hearing, or as otherwise agreed by the parties.

If the Athlete or other Person and the Results Management Authority agree to proceed with a single hearing before CAS, the matter shall be referred to the CAS hearing panel and be dealt with pursuant to these Rules.

CAS における一審制の聴聞会

7.6.1 世界規程第 8.5 項に従い、国際レベルの競技者、国内レベルの競技者その他の人に対して主張されたアンチ・ドーピング規則違反は、競技者又はその他の人が、結果管理機関及び WADA の同意をもって、事前の聴聞を要件とすることなく、又は当事者による別段の合意に従い、CAS の不服申立手続に従った CAS にて直接一審制の聴聞会において聴聞を受けることができる。

7.6.2 競技者又はその他の人及び結果管理機関が CAS における一審制の聴聞会により進めることに合意した場合、
hearing before CAS, it shall be the responsibility of the Results Management Authority to liaise in writing with WADA to determine whether it agrees to the proposal. Should WADA not agree (in its entire discretion), then the case shall be heard by the Results Management Authority’s hearing panel at first instance.

[Comment to Article 7.6.2: In the event that all relevant parties agree to refer the case to the CAS as a single instance, the Results Management Authority shall promptly notify any other Anti-Doping Organization with a right of appeal upon initiating the proceedings so that the latter may seek to intervene in the proceedings (if they wish to). The final decision rendered by the CAS shall not be subject to any appeal, save to the Swiss Federal Tribunal.]
PART FOUR: RESULTS MANAGEMENT – ADJUDICATION

8.0 Hearing Process

8.1 The rules of the Results Management Authority shall confer jurisdiction on hearing panels to hear and determine whether an Athlete or other Person subject to its anti-doping rules has committed an anti-doping rule violation and, if applicable, to impose the relevant Consequences. The Results Management Authority (or a Delegated Third Party upon delegation under Code Article 20) shall bring forward the charge before the hearing panel.

[Comment to Article 8.1: Results Management Authorities may also delegate the adjudication part of Results Management to Delegated Third Parties.]

It is not a Code requirement that a hearing should take place in person. Hearings may also take place remotely by the participants joining together using technology. There are no restrictions as to the technology that can or should be used, but include means such as conference calling, video conferencing technology or other online communication tools. Depending on the circumstances of a case, it may also be fair or necessary – for example, where all the facts are agreed and the only issue is as to the Consequences – to conduct a hearing “in writing”, based on written materials without an oral hearing.

8.2 For the purposes of Article 8.1, a wider pool of hearing panel members shall be established, from which the hearing panels for specific cases shall be nominated. Appointment to the pool must be made based on anti-doping experience, including legal, sports, medical and/or scientific expertise. All members of the pool shall be appointed for a period of no less than two (2) years (which may be renewable).

[Comment to Article 8.2: The number of potential hearing panel members appointed to the wider pool depends on the number of affiliates and the anti-doping history (including the number of anti-doping rule violations committed in the past years) of the Anti-Doping Organization. At the very least, the number of potential hearing panel members shall be sufficient to ensure that Hearing Processes are timely conducted and provide for replacement possibilities in the event of a conflict of interest.]

8.3 The applicable rules shall provide for an independent person or body to determine in their discretion the size and composition of a particular hearing panel to adjudicate an individual case. At least one appointed hearing panel member must have a legal background.

[Comment to Article 8.3: For example, the independent person may be a designated chairperson of the pool. The relevant rules should also provide for a mechanism for the event that the independent person or body has a conflict of interest.
interest (e.g. the chairperson may be replaced by a designated vice-chairperson in the event of a conflict of interest, or by the most senior hearing panel member with no conflict of interest, where there is no vice-chairperson or both the chairperson and vice-chairperson are in a situation of conflict).

The size and composition of the hearing panel may vary depending on the nature of the charge and the evidence put forward. The hearing panel may be composed of a single adjudicator. The chairperson of the pool can be appointed (or appoint themselves if applicable) to sit as single adjudicator or hearing panel member. If a single adjudicator is appointed, they shall have a legal background.

8.4 Upon appointment to a hearing panel, each hearing panel member shall sign a declaration that there are no facts or circumstances known to him/her which might call into question their impartiality in the eyes of any of the parties, other than any circumstances disclosed in the declaration. If such facts or circumstances arise at a later stage of the Hearing Process, the relevant hearing panel member shall promptly disclose them to the parties.

8.4 聴聞パネルへの任命にあたり、各聴聞パネルメンバーは、宣言書で開示された状況以外に、いかなる当事者の目線においても自己の公平性に疑義をもたる事実又は既に狀況について自己が知らないことを示す宣言書に署名するものとする。当該事実又は事態が聴聞手続の後の段階で発生した場合には、該当する聴聞パネルメンバーはそれを当事者に速やかに開示することとする。

[Comment to Article 8.4: For example, any member who is in any way connected with the case and/or the parties – such as family or close personal/professional ties and/or an interest in the outcome of the case and/or having expressed an opinion as to the outcome of the particular case – must openly disclose on the declaration all circumstances that might interfere with the impartial performance of their functions. To assess whether a hearing panel member is impartial, the Results Management Authority may take into account the principles set out in the IBA Guidelines on Conflicts of Interest in International Arbitration as updated from time to time available at https://www.ibanet.org.]

8.5 The parties shall be notified of the identity of the hearing panel members appointed to hear and determine the matter and be provided with their declaration at the outset of the Hearing Process. The parties shall be informed of their right to challenge the appointment of any hearing panel member if there are grounds for potential conflicts of interest within seven (7) days from the ground for the challenge having become known. Any challenge shall be decided upon by an independent person from the wider pool of hearing panel members or by an independent institution.

8.5 当事者は、聴聞手続の冒頭で、案件を聴聞し、決定するために任命された聴聞パネルメンバーの身元について通知を受け、その宣言書の提供を受けることができる。当事者は、利益相反の可能性の根拠があった場合には、忌避の根拠を知ってから7日以内に、聴聞パネルメンバーの任命に対し忌避を申し立てることに有する旨の通知を受けるものとする。忌避は、聴聞パネルメンバーのより大きなリストの中から選定された独立した人、又は独立の機関により、決定されるものとする。

[Comment to Article 8.5: For example, the independent person may be a designated chairperson of the pool. The relevant rules should also provide for a mechanism for the event that the independent person is the person subject to the challenge or is one of the other members of that particular hearing panel (e.g. the designated independent person may be replaced in these circumstances by a vice-chairperson or other designated senior hearing panel member).]
8.6 The rules governing the activities of the Results Management Authority shall guarantee the Operational Independence of hearing panel members.

[Comment to Article 8.6: As per Comment to Code Article 8.1, Operational Independence means that (1) board members, staff members, commission members, consultants and officials of the Results Management Authority or its affiliates (e.g. member federation or confederation), as well as any person involved in the investigation and pre-adjudication of the matter, cannot be appointed as members and/or clerks (to the extent that such clerk is involved in the deliberation process and/or drafting of any decision) of hearing panels of that Results Management Authority and (2) that hearing panels shall be in a position to conduct the hearing and decision-making process without interference from the Results Management Authority or any third party.]

8.7 Anti-Doping Organizations shall provide adequate resources to ensure that hearing panels are able to fulfil their tasks efficiently and independently and otherwise in accordance with this Article 8.

[Comment to Article 8.7: All agreed fees and reasonable expenses of the hearing panels shall be timely paid by the Results Management Authority.]

8.8 The Hearing Process shall respect, at a minimum, all of the following principles:

a) The hearing panel must remain fair, impartial and Operationally Independent at all times;

b) The Hearing Process shall be accessible and affordable;

[Comment to Article 8.8 b): Procedural fees, if any, shall be set at a level that does not prevent the accused Person from accessing the hearing. When necessary, the Results Management Authority and/or the relevant hearing panel should consider establishing a legal aid mechanism in order to ensure such access.]

c) The Hearing Process shall be conducted within a reasonable time;

[Comment to Article 8.8 c): All decisions shall be issued and notified promptly after the hearing in person or, if no hearing in person is requested, after the parties have filed their written submissions. Save in complex matters, this timeframe should not exceed two (2) months.]

d) The right to be informed in a fair and timely manner of the asserted anti-doping rule violation(s), the right to be represented by counsel at the Athlete or other Person’s own expense, the right of access to and to present relevant evidence, the right to submit written and oral submissions, the right to call and examine witnesses, and the right to an
interpreter at the hearing at the Athlete or other Person's own expense; and

[Comment to Article 8.8 d): In principle, where the hearing is in person, it should be composed of an opening phase, where the parties are given an opportunity to briefly present their case, an evidentiary phase, where the evidence is assessed and witnesses and experts (if any) are heard, and a closing phase, where all parties are given an opportunity to present their final arguments in light of the evidence.]

e) The right for the Athlete or the other Person to request a public hearing. The Results Management Authority may also request a public hearing provided that the Athlete or the other Person has provided his/her written consent to the same.

[Comment to Article 8.8 e): However, the Athlete or other Person’s request may be denied by the hearing panel in the interest of morals, public order, national security, where the interests of Minors or the protection of the private life of the parties so require, where publicity would prejudice the interests of justice or where the proceedings are exclusively related to questions of law.]

8.9 Hearing Processes held in connection with Events may be conducted by an expedited process as permitted by the rules of the relevant Anti-Doping Organization and the hearing panel.

e) 競技者又はその他の人が公開の聴聞会を要請する権利。結果管理機関もまた、競技者又はその他の人が書面により同意しているのであれば、公開の聴聞会を要請することができる。

[第 8.8 項 e）の解説：しかし、競技者又はその他の人の要請は、道徳、公的秩序、国家安全の観点から、18 歳未満の者の利益又は当事者の私的生活の保護から必要とされる場合、公開が正義を損なう場合、又は手続が法的問題にのみ関連する場合には、聴聞パネルにより拒否される場合がある。]

8.9 競技大会に関連して行われる聴聞手続は、関連するアンチ・ドーピング機関の規則及び聴聞パネルが許容するとおり、簡単な手続により行われる場合がある。
9.0 Decisions

9.1 Content

9.1.1 Results Management decisions or adjudications by Anti-Doping Organizations must not purport to be limited to a particular geographic area or sport and shall address and determine the following issues:

a) Jurisdictional basis and applicable rules;

b) Detailed factual background;

c) Anti-doping rule violation(s) committed;

d) Applicable Consequences; and

[Comment to Article 9.1.1 b): For instance, where the violation is based on an Adverse Analytical Finding, the decision shall set out inter alia the date and place of the Sample Collection Session, the type of Sample collection (blood or urine), whether the control was Out-of-Competition or In-Competition, the Prohibited Substance detected, the WADA-accredited Laboratory that performed the analysis, if the “B” Sample analysis was requested and/or performed as well as the results of the analysis. For any other violation, a full and detailed description of the facts shall be made.]

c) Anti-doping rule violation(s) committed;

[Comment to Article 9.1.1 c): Where the violation is based on an Adverse Analytical Finding, the decision shall inter alia set out that there was no departure from the International Standards, or that the alleged departure(s) did or did not cause the Adverse Analytical Finding and demonstrate that the violation of Code Article 2 is made out (see Code Article 2.1.2). For any other violation, the hearing panel shall assess the evidence presented and explain why it considers that the evidence presented by the Results Management Authority meets or does not meet the required standard of proof. In case the hearing panel considers that the anti-doping rule violation(s) is/are established, it shall expressly indicate the anti-doping rule(s) violated.]

d) Applicable Consequences; and

[Comment to Article 9.1.1 d): The decision shall identify the specific provisions on which the sanction, including any reduction or suspension, is based and provide reasons justifying the imposition of the relevant Consequences. In particular, where the applicable rules grant discretion to the hearing panel (e.g. for Specified or Contaminated Substances under Code Article 10.6.1.1 and 10.6.1.2), the decision shall explain why the period of Ineligibility imposed is appropriate. The decision shall also indicate the start date of the period of Ineligibility (if any) and provide justifications in the event that this date is earlier than the date of the decision (see Code Article 10.13.1). The decision shall also indicate the period of Disqualification, with justification in the event that certain results are not Disqualified for reasons of fairness (Code Article 10.10 of the Code), and any forfeiture of medals or prizes. The

9.0 決定

9.1 内容

9.1.1 アンチ・ドーピング機関による結果管理決定又は裁定は、特定の地理的場所又は競技に限定されることがないことが原則であり、以下の事項を取り扱い、決定するものとする。

a) 管轄の根拠及び適用規則

b) 詳細な事実的背景

[第9.1.1項b)の解説: 例えば、違反が、違反が疑われる分析報告に基づく場合には、決定文には、とりわけ、検体採取セッションの日付及び時間、検体採取の種類（血液又は尿）、ドーピング・コントロールが競技会外又は競技会（時）であったか、検出された禁止物質、分析を行った WADA 認定分析機関、「B」検体の分析が要請され及び/又は実施されたか、並びに当該分析の結果を規定するものとする。他の違反については、事実の完全かつ詳細な記載がなされるものとする。]

c) 行われたアンチ・ドーピング規則違反

[第9.1.1項c)の解説: 違反が、違反が疑われる分析報告に基づく場合には、決定文には、とりわけ、国際基準からの乖離がなかったこと、又は主張された乖離が違反が疑われる分析報告の原因となり若しくはなかったことを記載し、世界規程第 2 項の違反が行われたことを論証しなければならない（世界規程第 2.1.2 項を参照すること）。他の違反については、聴聞パネルは、提示された証拠を評価し、結果管理機関が提示した証拠が要請された証明の程度を満たし又は満たさないかを理解し、決定するものとする。聴聞パネルが、アンチ・ドーピング規則違反が立証されたと考える場合には、違反されたアンチ・ドーピング規則を明示的に示すものとする。]

d) 適用される措置、並びに

[第9.1.1項d)の解説: 決定文には、短縮又は停止を含む制裁措置の根拠となった具体的な条項を特定し、関連する措置を説明することを正当化する理由を提供するものとする。特に、適用規則が聴聞パネルに対し裁量を付与している場合（例えば、世界規程第 10.6.1.1.1 項及び第 10.6.1.2 項に基づく特定物質又は汚染物質について）には、決定文では、賦課された資格停止期間が適切である理由を説明するものとする。また、決定文では、資格停止期間（もしあれば）の開始日を示し、当該日付が決定日よりも早い場合にはこれを正当化する理由を提供するものとする（世界規程第 10.13.1 項を参照すること。）。また、決定文では、特定の成績が公正性を理由として失効させられなかった場合（世界規程第 10.10 項）には、これを正当化する理由を示し、失効期間について、並びにメダル及び賞賛の剥奪について示すものとする。また、決定文には、最終的
decision shall also set if (and to what extent) any period of Provisional Suspension is credited against any period of Ineligibility ultimately imposed, and set out any other relevant Consequences based on the applicable rules, including Financial Consequences. As per Code Article 7.5.1, Major Event Organizations shall, however, not be required to determine Ineligibility or Financial Consequences beyond the scope of their Event.

e) Appeal routes and deadline to appeal for the Athlete or other Person.

[Comment to Article 9.1.1 e): The decision shall indicate whether the Athlete is an International-Level Athlete for the purposes of the appeal route under Code Article 13. If this information is not available to the hearing panel, the hearing panel shall request the Results Management Authority to liaise with the relevant Anti-Doping Organization (e.g. the International Federation of the Athlete). The decision shall then set out the appropriate appeal route (including the address to which any appeal should be sent to) and the deadline to appeal.]

[Comment to Article 9.1.1: Results Management decisions include Provisional Suspension, save that a Results Management decision on Provisional Suspension shall not be required to determine whether an anti-doping rule violation was committed.]

9.1.2 A Results Management decision or adjudication by a Major Event Organization in connection with one of its Events may be limited in its scope but shall address and determine, at a minimum, the following issues: (i) whether an anti-doping rule violation was committed, the factual basis for such determination, and the specific Code Articles violated, and (ii) applicable Disqualifications under Code Articles 9 and 10.1, with any resulting forfeiture of medals, points and prizes.

[Comment to Article 9.1.2: With the exception of Results Management decisions by Major Event Organizations, each decision by an Anti-Doping Organization should address whether an anti-doping rule violation was committed and all Consequences flowing from the violation, including any Disqualifications other than Disqualification under Code Article 10.1 (which is left to the ruling body for an Event). Pursuant to Code Article 15, such decision and its imposition of Consequences shall have automatic effect in every sport in every country. For example, for a determination that an Athlete committed an anti-doping rule violation based on an Adverse Analytical Finding for a Sample taken In-Competition, the Athlete’s results obtained in the Competition would be Disqualified under Code Article 9 and all other competitive results obtained by the Athlete from the date the Sample was collected through the duration of the period of Ineligibility are also Disqualified under Code Article 10.10; if the Adverse Analytical Finding resulted from Testing at an Event, it would be the Major Event Organization’s responsibility to decide whether the Athlete’s other に賦課された資格停止期間から控除された暫定的資格停止期間の有無（及びその範囲）を規定し、金銭的措置を含む、適用規則に基づく他の関連措置について規定するものとする。しかし、世界規程第7.5.1項に従い、主要競技大会機関は、自己の競技大会の範囲を超えて資格停止又は金銭的措置について決定することは必要とされない。]

e) 競技者又はその他の人のための不服申立ての経路及び期限

[第9.1.1項e)の解説:決定文では、競技者が、世界規程第13条に基づく不服申立て経路の目的上、国際レベルの競技者であるか否かを示すものとする。聴聞パネルがこの情報を入手できない場合には、聴聞パネルは、結果管理機関に対し、関連するアンチ・ドーピング機関（例えば、競技者の国際競技連盟）と連携するよう求めるものとする。その後、決定文には（不服申立てが送付されるべき住所を含む）適切な不服申立て経路及び不服申立て期限を規定するものとする。]

[第9.1.1項の解説:結果管理決定文は、暫定的資格停止を含む。但し、暫定的資格停止に関する結果管理決定は、アンチ・ドーピング規則違反が行われたか否かを決定する必要はない。]

9.1.2 自己の競技大会の一つと関連した主要競技大会機関による結果管理決定又は裁定は、その範囲が限定される場合があるが、最低限、以下の事項を取り扱い、決定するものとする。①アンチ・ドーピング規則違反が行われたか否か、当該決定の事実上の根拠及び違反のなされた具体的な世界規程の条項、並びに②世界規程第9条及び第10.1項に基づく、適用される失効（結果として生じるメダル、得点及び褒賞の剥奪と共に）。

[第9.1.2項の解説:主要競技大会機関による結果管理決定を例外として、アンチ・ドーピング機関による各決定は、アンチ・ドーピング規則違反が行われたか否か、及び世界規程第10.1項に基づく失効以外の失効（競技大会の所轄組織の判断に任せられる。）を含む、違反から発生する措置の一切を取り扱うべきである。世界規程第15条に従い、当該決定及び措置の処理は、すべての国におけるすべての競技について自動的な効果を有するものとする。例えば、競技者、競技会（時には採取された検体について違反が疑われる分析報告に基づくアンチ・ドーピング規則違反を行った旨の判断については、競技会で獲得された競技者の結果は世界規程第9条に基づき失効し、検体採取日から資格停止期間を通じて競技者により獲得された他のすべての競技成績も世界規程第10.10項に基づき失効するが、違反が疑われる分析報告が競技会での検査から発生した場合には、検体採取前の競技会における競技者のその個人成績も世界規程第10.1項に基づき失効するか否かを判断することについては主要競技大会機関が責任を負う。]
9.2 Notification

9.2.1 Decisions shall be promptly notified by the Results Management Authority to the Athlete or other Person and to other Anti-Doping Organizations with a right of appeal under Code Article 13.2.3 and shall promptly be reported into ADAMS. Where the decision is not in English or French, the Results Management Authority shall provide an English or French summary of the decision and of the supporting reasons as well as a searchable version of the decision.

9.2.2 An Athlete or other Person subject to a period of Ineligibility shall be made aware by the Results Management Authority of their status during Ineligibility, including the Consequences of a violation of the prohibition of participation during Ineligibility, pursuant to Code Article 10.14. The Results Management Authority shall ensure that the period of Ineligibility is duly respected within its sphere of competence. The Athlete or other Person should also be made aware that they may still provide Substantial Assistance.

9.2.3 An Athlete subject to a period of Ineligibility should also be made aware by the Results Management Authority that they remain subject to Testing during the period of Ineligibility.

9.2.4 Where, further to notification of the decision, an Anti-Doping Organization with a right of appeal requests a copy of the full case file pertaining to the decision, it shall be provided promptly by the Results Management Authority.

[Comment to Article 9.2.4: The case file shall contain all documents relating to the case. For an analytical case, it shall include at a minimum the Doping Control form, Laboratory results and/or Laboratory Documentation Package(s) (if issued), any submissions and exhibits and/or correspondence of the parties and all other documents relied upon by the hearing body. The case file should be sent by email in an organized manner with a table of contents.]

9.2.5 If the decision concerns an Adverse Analytical Finding or Atypical Finding, and after any deadline to appeal has elapsed and no appeal has been filed against the decision, the Results Management Authority shall promptly notify the relevant Laboratory that the matter has been finally disposed of.

10.0 Appeals

10.1 The rules governing appeal rights and avenues are set out at Code Article 13.

10.2 With respect to national appellate instances within the...
meaning of Code Article 13.2.2:

a) The appointment of hearing panel members and the Hearing Process on appeal are governed by Article 8 mutatis mutandis. In addition to being fair, impartial and Operationally Independent, a hearing panel on appeal shall also be Institutionally Independent;

[Comment to Article 10.2 a): For the purposes of this provision, hearing panels on appeal shall be fully Institutionally Independent from the Results Management Authority. They must therefore not in any way be administered by, connected or subject to the Results Management Authority.]

b) The appeal decision rendered by an appeal body shall comply with the requirements of Article 9.1;

c) The appeal decision shall promptly be notified by the Results Management Authority to the Athlete or other Person and to the other Anti-Doping Organizations that would have been entitled to appeal the prior instance decision under Code Article 13.2.3;

d) The further notification requirements at Article 9.2 shall apply mutatis mutandis.

10.3 With respect to appeals before CAS:

a) The appeal procedure shall be governed by the Code of Sports-related Arbitration;

b) All parties to any CAS appeal must ensure that WADA and any other party, which would have had a right of appeal and is not a party to the CAS appeal, has been given timely notice of the appeal;

c) No settlement embodied in an arbitral award rendered by consent of the parties as per R56 of the Code of Sports-related Arbitration shall be entered into by an Anti-Doping Organization without WADA’s written approval. Where the parties to the CAS proceedings are envisaging settling the matter by way of a settlement embodied in an arbitral award rendered by consent of the parties, the Anti-Doping Organization that is a party to the proceedings shall immediately notify WADA and provide it with all necessary information in this respect;

d) Any Anti-Doping Organization that is a party to an appeal before CAS shall promptly provide the CAS award to the other Anti-Doping Organizations that would have been entitled to appeal under Code Article 13.2.3; and

e) The requirements of Articles 9.2.2 to 9.2.4 shall apply mutatis mutandis.

11.0 Violation of the Prohibition Against Participation

申立ての審理については、以下のとおりである。

a) 不服申立てにおける聴聞パネルメンバーの任命及び聴聞手続については第 8 条が準用される。公正、公平及び運用上の独立性に加えて、不服申立てにおける聴聞パネルは、組織的な独立性を有するものとする。

【第 10.2 項 a) の解説：この条項において、不服申立てにおける聴聞パネルは、結果管理機関から完全に組織的な独立性を有するものとする。よって、それはいかなる方法によっても結果管理機関により運営され、関連し、又はこれに服してはならない。】

b) 不服申立機関により付け与された不服申立決定は、第 9.1 項の要件を遵守するものとする。

c) 不服申立決定は、結果管理機関から競技者又はその他の人、及び、第 13.2.3 項に基づき従前の審理決定に対し不服申立てを行う権利を有していたであろう他のアンチ・ドーピング機関に対し速やかに通知されるものとする。

d) 第 9.2 項における更なる通知要件が準用されるものとする。

10.3 CAS に対する不服申立てについては、以下のとおりである。

a) 不服申立手続は、スポーツ関連仲裁規則に準拠するものとする；

b) CAS の不服申立てのすべての当事者は、WADA、及び、不服申立ての権利を有していたが CAS の不服申立ての当事者ではない他の当事者が、当該不服申立てについて適時的通知を受けたことを確保しなければならない。

c) スポーツ関連仲裁規則の R56 に従い当事者の同意により下された仲裁判断において具体化された和解は、WADA の書面による同意なくアンチ・ドーピング機関がこれを行ってはならない。CAS の手続の当事者が当事者の同意により下された仲裁判断において具体化された和解の方法によって当該案件を解決することを想定している場合には、当該手続の当事者であるアンチ・ドーピング機関は、直ちにこれを WADA に通知し、これに関して必要な情報の一切を WADA に提供するものとする。

d) CAS に対する不服申立ての当事者であるアンチ・ドーピング機関は、世界規程第 13.2.3 項に基づき不服申立ての権利を有していたであろうその他のアンチ・ドーピング機関に対し、CAS の仲裁判断を速やかに提供するものとする。並びに、

e) 第 9.2.2 項から第 9.2.4 項の要件が準用されるものとする。

11.0 資格停止期間中の参加禁止の違反
During Ineligibility

11.1 In the event that an Athlete or other Person is suspected to have violated the prohibition against participation during Ineligibility pursuant to Code Article 10.14, the Results Management relating to this potential violation shall comply with the principles of this International Standard mutatis mutandis.

[Comment to Article 11.1: In particular, the Athlete or other Person shall receive a notification letter in accordance with Article 5.3.2 mutatis mutandis, a letter of charge in accordance with Article 7 mutatis mutandis and be afforded the right to a hearing as per Article 8.]

11.1 競技者又はその他の人が世界規程第 10.14 項に従い資格停止期間中の参加禁止に違反した旨疑われる場合には、この違反の可能性に関連する結果管理は、この国際基準の原則を準用してこれを遵守するものとする。

〔第 11.1 項の解説：特に、競技者又はその他の人は、第 5.3.2 項を準用したところに従い通知文書を、及び、第 7 条を準用したところに従い責任追及文書を受領し、第 8 条に従い聴聞を受ける権利を付与されるものとする。〕
ANNEX A – REVIEW OF A POSSIBLE FAILURE TO COMPLY

A.1 Responsibility

A.1.1 The Results Management Authority or Testing Authority (as applicable) is responsible for ensuring that:

a) When the possible Failure to Comply comes to its attention, it notifies WADA, and instigates review of the possible Failure to Comply based on all relevant information and documentation;

b) The Athlete or other Person is informed of the possible Failure to Comply in writing and has the opportunity to respond in accordance with Article 5.3.2 of the International Standard for Results Management;

c) The review is conducted without unnecessary delay and the evaluation process is documented; and

d) If it decides not to move forward with the matter, its decision is notified in accordance with Article 5.4 of the International Standard for Results Management.

A.1.2 The DCO is responsible for providing a detailed written report of any possible Failure to Comply.

A.2 Requirements

A.2.1 Any potential Failure to Comply shall be reported by the DCO to the Results Management Authority (or Testing Authority as applicable) and/or followed up by the Testing Authority and reported to the Results Management Authority as soon as practicable.

A.2.2 If the Results Management Authority determines that there has been a potential Failure to Comply, the Athlete or other Person shall be promptly notified in accordance with Article 5.3.2 of the International Standard for Results Management and further Results Management shall be conducted as per Article 5 et seq. of the International Standard for Results Management.

A.2.3 Any additional necessary information about the potential Failure to Comply shall be obtained from all relevant sources (including the Athlete or other Person) as soon as possible and recorded.

A.2.4 The Results Management Authority (and Testing Authority as applicable) shall establish a system for ensuring that the outcomes of its reviews into potential Failures to Comply are considered for Results Management action and, if applicable, for further planning and Target Testing.

付属文書 A－不遵守の可能性の審査

A.1 責任

A.1.1 結果管理機関又は検査管轄機関（該当する方）は、以下の事項を確保することについて責任を負う。

a）自己が不遵守の可能性について知った場合には、WADA に通知し、すべての関連情報及び文書に基づき不遵守の可能性について審査を開始すること。

b）競技者又はその他の人が不遵守の可能性について書面で通知を受け、「結果管理に関する国際基準」の第 5.3.2 項に従い回答する機会を有すること。

c）審査は不必要な遅延なく行われ、評価過程が文書化されること。並びに、

d）自己が当該案件を進行しない旨判定した場合には、その決定は「結果管理に関する国際基準」の第 5.4 項に従い通知されること。

A.1.2 DCO は、不遵守の可能性について書面による詳細な報告を提供することについて責任を負う。

A.2 要件

A.2.1 不遵守の可能性は、可及的速やかに、DCO から結果管理機関（又は該当する場合には検査管轄機関）に対し報告され、及び/又は検査管轄機関によりフォローアップされ、結果管理機関に報告されるものとする。

A.2.2 結果管理機関が、不遵守の可能性があった旨判定した場合には、競技者又はその他の人は「結果管理に関する国際基準」の第 5.3.2 項に従い速やかに通知を受け、「結果管理に関する国際基準」の第 5 条以下に従い更なる結果管理が行われるものとする。

A.2.3 不遵守の可能性に関する追加の必要情報は、可及的速やかにすべての関連情報源（競技者又はその他の人を含む。）から取得され、記録されるものとする。

A.2.4 結果管理機関（及び該当する場合には検査管轄機関）は、不遵守の可能性に関する自己の審査が結果管理の行動、並びに、該当する場合には、更なる計画及び特定対象検査について考慮されることを確保するための体制を確立するものとする。
B.1 Determining a Potential Whereabouts Failure

B.1.1 Three (3) Whereabouts Failures by an Athlete within any 12-month period amount to an anti-doping rule violation under Code Article 2.4. The Whereabouts Failures may be any combination of Filing Failures and/or Missed Tests declared in accordance with Article B.3 and adding up to three (3) in total.

[Comment to Article B.1.1: While a single Whereabouts Failure will not amount to an anti-doping rule violation under Code Article 2.4, depending on the facts, it could amount to an anti-doping rule violation under Code Article 2.3 (Evading Sample Collection) and/or Code Article 2.5 (Tampering or Attempted Tampering with Doping Control).]

B.1.2 The 12-month period referred to in Code Article 2.4 starts to run on the date that an Athlete commits the first Whereabouts Failure being relied upon in support of the allegation of a violation of Code Article 2.4. If two (2) more Whereabouts Failures occur during the ensuing 12-month period, then Code Article 2.4 anti-doping rule violation is committed, irrespective of any Samples successfully collected from the Athlete during that 12-month period. However, if an Athlete who has committed one (1) Whereabouts Failure does not go on to commit a further two (2) Whereabouts Failures within the 12-months, at the end of that 12-month period, the first Whereabouts Failure “expires” for purposes of Code Article 2.4, and a new 12-month period begins to run from the date of their next Whereabouts Failure.

B.1.3 For purposes of determining whether a Whereabouts Failure has occurred within the 12-month period referred to in Code Article 2.4:

a) A Filing Failure will be deemed to have occurred (i) where the Athlete fails to provide complete information in due time in advance of an upcoming quarter, on the first day of that quarter, and (ii) where any information provided by the Athlete (whether in advance of the quarter or by way of update) transpires to be inaccurate, on the (first) date on which such information can be shown to be inaccurate; and

b) A Missed Test will be deemed to have occurred on the date that the Sample collection was unsuccessfully attempted.

B.1.4 Whereabouts Failures committed by the Athlete prior to retirement as defined in Article 4.8.7.3 of the International Standard for Testing and Investigations may be combined, for purposes of Code Article 2.4, with Whereabouts Failures committed by the Athlete after the Athlete again becomes available for Out-of-Competition Testing.

[Comment to Article B.1.4: For example, if an Athlete committed two (2) Whereabouts Failures in the six (6) months prior to their retirement, then if they commit another...]

付属文書 B－居場所情報関連義務違反のための結果管理

B.1 居場所情報関連義務違反の可能性の判定

B.1.1 12ヶ月の期間内における競技者による3回の居場所情報関連義務違反は、世界規程第2.4項に基づくアンチ・ドーピング規則違反に該当する。居場所情報関連義務違反は、第B.3項に従い宣言され、合計して3回の提出義務違反及び/又は検査未了の組み合わせである場合がある。

[B.1.1項の解説: 単独の居場所情報関連義務違反は世界規程第2.4項に基づくアンチ・ドーピング規則違反に該当しないものの、事実によっては、世界規程第2.3項（検体採取の回避）又は世界規程第2.5項（ドーピング・コントロールの不正干渉又は不正干渉の企て）の違反に基づくアンチ・ドーピング規則違反に該当する場合がある。]

B.1.2 世界規程第2.4項において言及される12ヶ月の期間は、世界規程第2.4項の違反の主張を支持するものとして、居場所情報関連義務違反を競技者が行った日に開始する。続く12ヶ月の期間中にさらに2回の居場所情報関連義務違反が発生した場合には、当該12ヶ月の期間中に競技者から成功裏に検体が採取されたとしても、世界規程第2.4項のアンチ・ドーピング規則違反が行われたことになる。しかし、1回の居場所情報関連義務違反を行った競技者がその12ヶ月間内にさらに2回の居場所情報関連義務違反を行わなかった場合には、当該12ヶ月の期間の終了時に、最初の居場所情報関連義務違反は世界規程第2.4項の目的上「期間満了」し、次の居場所情報関連義務違反の日から新規の12ヶ月の期間が開始する。

B.1.3 世界規程第2.4項において言及される12ヶ月の期間内に居場所情報関連義務違反が発生したか否かを判定するのににおいて、

a) 提出義務違反は、①競技者が次の四半期に先立ち、適時に完全な情報を提供しなかった場合は、当該四半期の初日に、また、②競技者により（四半期に先立ち又は更新の方法により）提供される情報が不正確である場合は、当該情報が不正確であることが示される（最初の）日に、発生したものとみなされる。並びに、

b) 検查未了は、検体採取の試みが失敗した日に発生したものとみなされる。

B.1.4 「検査及びドーピング調査に関する国際基準」の第4.8.7.3項において定義される引退に先立ち競技者が行った居場所情報関連義務違反は、世界規程第2.4項において、競技者が競技会外の検査に再度応じることができた後に競技者が行った居場所情報関連義務違反と組み合わせられる場合がある。

[B.1.4項の解説:例えば、競技者が自らの引退前の6ヶ月間に2回の居場所情報関連義務違反を行い、その後、自己が競技会外の検査に再度応じることができた最初...]

42
Whereabouts Failure in the first six (6) months in which they are again available for Out-of-Competition Testing, that amounts to a Code Article 2.4 anti-doping rule violation.

B.2 Requirements for a Potential Filing Failure or Missed Test

B.2.1 An Athlete may only be declared to have committed a Filing Failure where the Results Management Authority establishes each of the following:

a) That the Athlete was duly notified: (i) that they had been designated for inclusion in a Registered Testing Pool; (ii) of the consequent requirement to make Whereabouts Filing; and (iii) of the Consequences of any Failure to Comply with that requirement;

b) That the Athlete failed to comply with that requirement by the applicable deadline;

[Comment to Article B.2.1(b): An Athlete fails to comply with the requirement to make Whereabouts Filing (i) where they do not make any such filing, or where they fail to update the filing as required by Article 4.8.8.6 of the International Standard for Testing and Investigations; or (ii) where they make the filing or update but do not include all of the required information in that filing or update (e.g. they do not include the place where they will be staying overnight for each day in the following quarter, or for each day covered by the update, or omit to declare a regular activity that they will be pursuing during the quarter, or during the period covered by the update); or (iii) where they include information in the original filing or the update that is inaccurate (e.g., an address that does not exist) or insufficient to enable the Anti-Doping Organization to locate them for Testing (e.g., “running in the Black Forest”).]

c) In the case of a second or third Filing Failure, that they were given notice, in accordance with Article B.3.2(d), of the previous Filing Failure, and (if that Filing Failure revealed deficiencies in the Whereabouts Filing that would lead to further Filing Failures if not rectified) was advised in the notice that in order to avoid a further Filing Failure they must file the required Whereabouts Filing (or update) by the deadline specified in the notice (which must be within 48 hours after receipt of the notice) and yet failed to rectify that Filing Failure by the deadline specified in the notice; and

[Comment to Article B.2.1(c): All that is required is to give the Athlete notice of the first Filing Failure and an opportunity to avoid a subsequent one, before a subsequent Filing Failure may be pursued against them. In particular, it is not necessary to complete the Results Management process with respect to the first Filing Failure before pursuing a
d) That the Athlete’s failure to file was at least negligent. For these purposes, the Athlete will be presumed to have committed the failure negligently upon proof that they were notified of the requirements yet did not comply with them. That presumption may only be rebutted by the Athlete establishing that no negligent behavior on their part caused or contributed to the failure.

B.2.2 While Code Article 5.2 specifies that every Athlete must submit to Testing at any time and place upon request by an Anti-Doping Organization with Testing Authority over them, in addition, an Athlete in a Registered Testing Pool must specifically be present and available for Testing on any given day during the 60-minute time slot specified for that day in their Whereabouts Filing, at the location that the Athlete has specified for that time slot in such filing. Where this requirement is not met by the Athlete, it shall be pursued as an apparent Missed Test. If the Athlete is tested during such a time slot, the Athlete must remain with the DCO until the Sample collection has been completed, even if this takes longer than the 60-minute time slot. A failure to do so shall be pursued as an apparent violation of Code Article 2.3 (refusal or failure to submit to Sample collection).

B.2.3 To ensure fairness to the Athlete, where an unsuccessful attempt has been made to test an Athlete during one of the 60-minute time slots specified in their Whereabouts Filing, any subsequent unsuccessful attempt to test that Athlete (by the same or any other Anti-Doping Organization) during one of the 60-minute time slots specified in their Whereabouts Filing may only be counted as a Missed Test (or, if the unsuccessful attempt was because the information filed was insufficient to find the Athlete during the time slot, as a Filing Failure) against that Athlete if that subsequent attempt takes place after the Athlete has received notice, in accordance with Article B.3.2(d), of the original unsuccessful attempt.

[Comment to Article B.2.3: All that is required is to give the Athlete notice of one Missed Test or Filing Failure before a subsequent Missed Test or Filing Failure may be pursued against them. In particular, it is not necessary to complete the Results Management process with respect to the first Missed Test or Filing Failure before pursuing a second Missed Test or Filing Failure against the Athlete.]
were advised that they would be liable for a Missed Test if they were unavailable for Testing during the 60-minute time slot specified in their Whereabouts Filing at the location specified for that timeslot;

b) That a DCO attempted to test the Athlete on a given day in the quarter, during the 60-minute time slot specified in the Athlete’s Whereabouts Filing for that day, by visiting the location specified for that time slot;

c) That during that specified 60-minute time slot, the DCO did what was reasonable in the circumstances (i.e. given the nature of the specified location) to try to locate the Athlete, short of giving the Athlete any advance notice of the test;

d) That Article B.2.3 does not apply or (if it applies) was complied with; and

e) That the Athlete’s non-availability for Testing at the specified location during the specified 60-minute time slot was at least negligent. For these purposes, the Athlete will be presumed to have been negligent upon proof of the matters set out at sub-Articles B.2.4 (a) to (d). That presumption may only be rebutted by the Athlete establishing that no negligent behavior on their part caused or contributed to their failure (i) to be available for Testing at such location during such time slot, and (ii) to update their most recent Whereabouts Filing to give notice of a different location where they would instead be available for Testing during a specified 60-minute time slot on the relevant day.

B.3 Results Management for a Potential Whereabouts Failure

B.3.1 In accordance with Code Articles 7.1.6, the Results Management Authority in relation to potential Whereabouts Failures shall be the International Federation or the National Anti-Doping Organization with whom the Athlete in question files their whereabouts information.

[Comment to Article B.3.1: If an Anti-Doping Organization that receives an Athlete’s Whereabouts Filing (and so is their Results Management Authority for whereabouts purposes) removes the Athlete from its Registered Testing Pool after recording one or two Whereabouts Failures against them, then if the Athlete is put in another Anti-Doping Organization’s Registered Testing Pool, and that other Anti-Doping Organization starts receiving their Whereabouts Filing, then that other Anti-Doping Organization becomes the Results Management Authority for the purpose of the Whereabouts Failure.

B.3.2居場所情報関連義務違反の可能性のための結果管理

B.3.2.1 世界規程第7.1.6項に従い、居場所情報関連義務違反の可能性との関係において、結果管理機関は、対象の競技者の居場所情報提出先の国際競技連盟又は国内アント・ドーピング機関とする。

[Comment to Article B.3.2.1: 競技者が居場所情報提出で指定された60分の時間枠中に、当該時間枠が指定された場所における検査に応じられなかったときは、競技者が検査未了の責任を負う旨を告知されたこと。

b) DCOが、四半期におけるいずれかの日に、当該日にに関する競技者の居場所情報提出において指定された60分の時間枠の間、当該時間枠について指定された場所を訪れたことによって、競技者に対して検査を試みたこと。

c) 指定された60分の時間枠の間、DCOが、競技者に対して検査の事前通告を行うこと以外に、競技者の居場所を特定するために、当該状況の下で（すなわち、当該場所の性質に鑑みて）合理的と思われる行動をとること。

d) B.2.3項の定めが該当しないか又は（該当する場合には）その定めを満たすこと。

e) 指定された60分の時間枠の間、指定された場所において競技者が検査に応じなかったことについて、少なくとも過失があったこと。上記との関係において、競技者、競技者は、B.2.4項(a)から(d)までに規定された事項が証明された場合には、当該過失があったものと推定される。この推定に対しては、(i)当該時間枠の間、当該場所において検査に応じなかったこと、及び、(ii)関連日における、指定された60分の時間枠の間に、代わりに検査に応じることができた別の場所を通知することの直近の居場所情報提出の更新を怠ったことについて、自らの側にはかかる不履行を引き起こした又はその一因となった過失行為が何ら存在しないことを当該競技者が立証することによってのみ反証が可能である。]
the Results Management Authority in respect of all Whereabouts Failures by that Athlete, including those recorded by the first Anti-Doping Organization. In that case, the first Anti-Doping Organization shall provide the second Anti-Doping Organization with full information about the Whereabouts Failure(s) recorded by the first Anti-Doping Organization in the relevant period, so that if the second Anti-Doping Organization records any further Whereabouts Failure(s) against that Athlete, it has all the information it needs to bring proceedings against them, in accordance with Article B.3.4, for violation of Code Article 2.4.]

B.3.2 When a Whereabouts Failure appears to have occurred, Results Management shall proceed as follows:

a) If the apparent Whereabouts Failure has been uncovered by an attempt to test the Athlete, the Testing Authority shall timely obtain an Unsuccessful Attempt Report from the DCO. If the Testing Authority is different from the Results Management Authority, it shall provide the Unsuccessful Attempt Report to the Results Management Authority without delay, and thereafter it shall assist the Results Management Authority as necessary in obtaining information from the DCO in relation to the apparent Whereabouts Failure.

b) The Results Management Authority shall timely review the file (including any Unsuccessful Attempt Report filed by the DCO) to determine whether all of the Article B.2.1 requirements (in the case of a Filing Failure) or all of the Article B.2.4 requirements (in the case of a Missed Test) are met. It shall gather information as necessary from third parties (e.g., the DCO whose test attempt uncovered the Filing Failure or triggered the Missed Test) to assist it in this task.

c) If the Results Management Authority concludes that any of the relevant requirements have not been met (so that no Whereabouts Failure should be declared), it shall so advise WADA, the International Federation or National Anti-Doping Organization (as applicable), and the Anti-Doping Organization that uncovered the Whereabouts Failure, giving reasons for its decision. Each of them shall have a right of appeal against that decision in accordance with Code Article 13.

d) If the Results Management Authority concludes that all of the relevant requirements as set out in B.2.1 (Filing Failure) and B.2.4 (Missed Test) have been met, it should notify the Athlete within fourteen (14) days of the date of the apparent Whereabouts Failure. The notice shall include sufficient details of the apparent Whereabouts Failure to enable the Athlete to respond meaningfully, and shall give the Athlete a reasonable deadline to respond, advising whether they admit the Whereabouts Failure and, if they do not admit to the Whereabouts Failure, then an explanation as to why not. The notice should also advise the Athlete that three (3) Whereabouts Failures in any 12-month period is a Code Article 2.4 anti-doping rule violation, and should note whether they had any other Whereabouts Failures recorded against them in the previous twelve (12) months. In the case of a Filing Failure, B.3.2 居場所情報関連義務違反が発生したとみられる場合には、結果管理は以下のとおり進めるものとする。

a) 競技者が検査を試みにより明らかに居場所情報関連義務違反が発覚した場合には、検査管轄機関は DCO か ら試みの失敗に関する報告を適時に取得するものとする。検査管轄機関が結果管理機関と異なる場合には、検 査管轄機関は試みの失敗に関する報告を結果管理機関に送りuo提供し、その後、明らかに居場所情報関連義務違反が発覚した場合には、 DCO から情報を取得するに際し、必要に応じて、結果管理機関を支援するものとする。

b) 結果管理機関は、提出義務違反の場合は B.2.1 項の要件の一切、又は、検査未了の場合には B.2.4 項 の要件の一切が充足されているか判断するために、DCO の提出した試みの失敗に関する報告を含むファイルを適時に審査するものとする。結果管理機関は、その作業について支援するために、第三者（例えば、その 検査の試みが提出義務違反の発覚につながり又は検査未了の原因となった DCO）から、必要に応じて、情報を 収集するものとする。

c) 結果管理機関において、関連要件のいずれかが満た されていない（居場所情報関連義務違反が認定されるべき でない）と結論づけた場合、かかる決定の理由をもと に、WADA、国際競技連盟若しくは国内アンチ・ドーピ ング機関（適用される方）及び居場所情報関連義務違反を明らかにしたアンチ・ドーピング機関に対し、その旨 を通知するものとする。これらの各機関は、世界規程第 13 条に従い、かかる決定に対する不服申立てをする権利 を有する。

d) 結果管理機関が、B.2.1 項（提出義務違反）及び B.2.4 項（検査未了）に定める該当する要件の一切が充足さ れた旨結論づけた場合には、当該結果管理機関は、明らかな 居場所情報関連義務違反の日から、14 日以内に競技者に 通知するものとする。当該通知は競技者が意味ある回答 ができるよう、当該明白な居場所情報関連義務違反に関 する十分な詳細を含むものとし、当該競技者が当該居場 所情報関連義務違反を自認するか、または当該居場所情 報関連義務違反を自認しない場合には自認しない理由に 関する説明を提供するよう当該競技者に連絡のうえ、当該競 技者に回答するための合理的な期限を付与するものとする。また当該通知においては、12 ヶ月の期間中に おける 3 回の居場所情報関連義務違反は世界規程第 2.3 条のアンチ・ドーピング規則違反に該当し、従前の 12 ケ ヶ月間に自己に対し他の居場所情報関連義務違反が記録
the notice must also advise the Athlete that in order to avoid a further Filing Failure they must file the missing whereabouts information by the deadline specified in the notice, which must be within 48 hours after receipt of the notice.

e) If the Athlete does not respond within the specified deadline, the Results Management Authority shall record the notified Whereabouts Failure against them.

If the Athlete does respond within the deadline, the Results Management Authority shall consider whether their response changes its original decision that all of the requirements for recording a Whereabouts Failure have been met.

i. If so, it shall so advise the Athlete, WADA, the International Federation or National Anti-Doping Organization (as applicable), and the Anti-Doping Organization that uncovered the Whereabouts Failure, giving reasons for its decision. Each of them shall have a right of appeal against that decision in accordance with Code Article 13.

ii. If not, it shall so advise the Athlete (with reasons) and specify a reasonable deadline by which they may request an administrative review of its decision. The Unsuccessful Attempt Report shall be provided to the Athlete at this point if it has not been provided to them earlier in the process.

f) If the Athlete does not request an administrative review by the specified deadline, the Results Management Authority shall record the notified Whereabouts Failure against them. If the Athlete does request an administrative review before the deadline, it shall be carried out, based on the papers only, by one or more persons not previously involved in the assessment of the apparent Whereabouts Failure. The purpose of the administrative review shall be to determine anew whether or not all of the relevant requirements for recording a Whereabouts Failure are met.

g) If the conclusion following administrative review is that all of the requirements for recording a Whereabouts Failure are not met, the Results Management Authority shall so advise the Athlete, WADA, the International Federation or National Anti-Doping Organization (as applicable), and the Anti-Doping Organization that uncovered the Whereabouts Failure, giving reasons for its decision. Each of them shall have a right of appeal against that decision in accordance with Code Article 13. On the other hand, if the conclusion is that all of the requirements for recording a Whereabouts Failure are met, it shall notify the Athlete and shall record the notified Whereabouts Failure against them.

B3.3 The Results Management Authority shall promptly report a decision to record a Whereabouts Failure against an Athlete.

i. その場合、かかる決定の理由とともに、WADA、国際競技連盟若しくは国内アンチ・ドーピング機関（適用される方）及び居場所情報関連義務違反を明らかにしたアンチ・ドーピング機関に対し、かかる決定の理由とともに、その旨を通じて通知するものとする。これらの各機関は、世界規程第13条に従い、かかる決定に対する不服申立てをする権利を有する。

ii. 変更されない場合には、結果管理機関は競技者に（理由とともに）かかる旨を通知し、当該競技者が結果管理機関の決定について不服審査を要請することのできる合理的な期限を特定するものとする。試みの失敗に関する報告は、手続のより早期において競技者に提供されていなかった場合には、かかる時点において当該競技者に提供されるものとする。

f) 競技者が特定された期限までに不服審査を要請しない場合、結果管理機関は、競技者に通知された居場所情報関連義務違反を記録するものとする。競技者が、期限までに不服審査を要請した場合、書面のみを基にし、明白な居場所情報関連義務違反の評価に関与したことのない1名以上の者により、審査を行うものとする。不服審査の目的は、居場所情報関連義務違反を記録するための関連要件すべてが満たされたか否かを新たに判断することにある。

g) 不服審査を経て、居場所情報関連義務違反を記録するための関連要件すべてが満たされたものではないという結論になった場合、結果管理機関は、理由とともに、WADA、国際競技連盟若しくは国内アンチ・ドーピング機関（適用される方）及び居場所情報関連義務違反を明らかにしたアンチ・ドーピング機関に対して、その旨を通じて通知するものとする。これらの各機関は、世界規程第13条に従い、かかる決定に対する不服申立てをする権利を有する。他方、居場所情報関連義務違反を記録するための関連要件すべてが満たされたという結論になった場合、結果管理機関は、競技者にその旨を通じて、当該競技者に対して通知された居場所情報関連義務違反を記録するものとする。

B3.3.3 結果管理機関は、競技者に対する居場所情報関連義務違反を記録する決定については、WADA及びすべて
Athlete to WADA and all other relevant Anti-Doping Organizations, on a confidential basis, via ADAMS.

B.3.4 Where three (3) Whereabouts Failures are recorded against an Athlete within any 12-month period, the Results Management Authority shall notify the Athlete and other Anti-Doping Organizations in accordance with Article 5.3.2 of the International Standard for Results Management alleging violation of Code Article 2.4 and proceed with Results Management in accordance with Article 5 et seq. of the International Standard for Results Management. If the Results Management Authority fails to bring such proceedings against an Athlete within 30-days of WADA receiving notice of the recording of that Athlete's third Whereabouts Failure in any 12-month period, then the Results Management Authority shall be deemed to have decided that no anti-doping rule violation was committed, for purposes of triggering the appeal rights set out at Code Article 13.2.

B.3.5 An Athlete asserted to have committed a Code Article 2.4 anti-doping rule violation shall have the right to have such assertion determined at a full evidentiary hearing in accordance with Code Article 8 and Articles 8 and 10 of the International Standard for Results Management. The hearing panel shall not be bound by any determination made during the Results Management process, whether as to the adequacy of any explanation offered for a Whereabouts Failure or otherwise. Instead, the burden shall be on the Anti-Doping Organization bringing the proceedings to establish all of the requisite elements of each alleged Whereabouts Failure to the comfortable satisfaction of the hearing panel. If the hearing panel decides that one (or two) Whereabouts Failure(s) have been established to the required standard, but that the other alleged Whereabouts Failure(s) has/have not, then no Code Article 2.4 anti-doping rule violation shall be found to have occurred. However, if the Athlete then commits one (or two, as applicable) further Whereabouts Failure(s) within the relevant 12-month period, new proceedings may be brought based on a combination of the Whereabouts Failure(s) established to the satisfaction of the hearing panel in the

B.3.3 項の解釈：誤解を避けるために言及すると、結果管理機関は、(検査計画目的のため等)適切であると考えた場合、結果管理手続のより早い段階において、明白な居場所情報関連義務違反について他の関連するアンチ・ドーピング機関に対し(厳秘扱い)で通知する権限がある。さらに、アンチ・ドーピング機関は、自己の活動に関する一般的な統計的報告書を発行して、自己の管理下の競技者の特定の期間の居場所情報関連義務違反の自己管理機関による一般的な形で示すことができる。但し、関連する競技者の身元が明らかになるおそれのある情報については、一切公開しないものとする。アンチ・ドーピング機関は、世界規程第2.4項の手続前に、特定の競技者について居場所情報関連義務違反の記録が存在するか(若しくは存在しないか)又は特定のアンチ・ドーピング機関に通知し、(結果管理に関する国際基準)の第5条2項に従い、競技者その他のアンチ・ドーピング機関に通知し、(結果管理に関する国際基準)の第5条以下に従い結果管理を進めるものとする。結果管理機関が、いずれかの12ヶ月の期間における競技者の3回目の居場所情報関連義務違反の通知をWADAが受領した日から30日以内に、競技者に対する手続を進めなかった場合、世界規程第13.2項に定める不服申立て等の権利との関係では、結果管理機関はアンチ・ドーピング規則違反が行われていない旨決定したものとみなされる。
previous proceedings (in accordance with Code Article 3.2.3) and the Whereabouts Failure(s) subsequently committed by the Athlete.

[Comment to Article B.3.5: Nothing in Article B.3.5 is intended to prevent the Anti-Doping Organization challenging an argument raised on the Athlete’s behalf at the hearing on the basis that it could have been but was not raised at an earlier stage of the Results Management process.]

B.3.6 A finding that an Athlete has committed a Code Article 2.4 anti-doping rule violation has the following Consequences: (a) imposition of a period of Ineligibility in accordance with Code Article 10.3.2 (first violation) or Code Article 10.9 (subsequent violation(s)); and (b) in accordance with Code Article 10.10 (Disqualification, unless fairness requires otherwise) of all individual results obtained by the Athlete from the date of the Code Article 2.4 anti-doping rule violation through to the date of commencement of any Provisional Suspension or Ineligibility period, with all of the resulting Consequences, including forfeiture of any medals, points and prizes. For these purposes, the anti-doping rule violation shall be deemed to have occurred on the date of the third Whereabouts Failure found by the hearing panel to have occurred. The impact of any Code Article 2.4 anti-doping rule violation by an individual Athlete on the results of any team for which that Athlete has played during the relevant period shall be determined in accordance with Code Article 11.

| 報関連義務違反と、その後に競技者が行った居場所情報開関連義務違反を含算して新たな手続が開始される場合がある。 |

[B.3.5 項の解説: B.3.5 項の規定は、結果管理手続の初期の段階において提示することが可能であったにもかかわらず提示されなかったことを理由として、聴聞会において、競技者のために提起される異議に対するアンチ・ドーピング機関の反論を妨げることを意図するものではない]

B.3.6 競技者が世界規程第 2.4 項のアンチ・ドーピング規則違反を行った旨の判断は、以下の措置を伴う。(a) 世界規程第 10.3.2 項（最初の違反）又は世界規程第 10.9 項（後続的な違反）に従った、資格停止期間の賦課、及び(b) 世界規程第 10.10 項（公平性により別途要請される場合を除き、失効する）に従った。世界規程第 2.4 項のアンチ・ドーピング規則違反の日から暫定的資格停止又は資格停止期間の開始までに競技者により取得された個人成績の一切の失効（メダル・得点・褒賞の剥奪を含む。）。これらの目的において、アンチ・ドーピング規則違反は、聴聞パネルが、行われた旨判断した 3 回目の居場所情報開関連義務違反の日に発生したものとみなされる。該当する期間中に競技者が競技したチームの成績に対する、個人の競技者による世界規程第 2.4 項のアンチ・ドーピング規則違反の影響は、世界規程第 11 条に従い判断されるものとする。]
C.1 Administrative Management

C.1.1 The requirements and procedures described in this Annex apply to all modules of the Athlete Biological Passport except where expressly stated or implied by the context.

C.1.2 These processes shall be administered and managed by an Athlete Passport Management Unit on behalf of the Passport Custodian. The Athlete Passport Management Unit will initially review profiles to facilitate targeting recommendations for the Passport Custodian when appropriate or refer to the Experts as required. Management and communication of the biological data, Athlete Passport Management Unit reporting and Expert reviews shall be recorded in ADAMS and be shared by the Passport Custodian with other Anti-Doping Organizations with Testing Authority over the Athlete to coordinate further Passport Testing as appropriate. A key element for Athlete Biological Passport management and communication is the Athlete Passport Management Unit report in ADAMS, which provides an overview of the current status of the Athlete’s Passport including the latest targeting recommendations and a summary of the Expert reviews.

C.1.3 This Annex describes a step-by-step approach to the review of an Athlete’s Passport:

a) The review begins with the application of the Adaptive Model.

b) In case of an Atypical Passport Finding or when the Athlete Passport Management Unit considers that a review is otherwise justified, an Expert conducts an initial review and returns an evaluation based on the information available at that time.

c) In case of a “Likely doping” initial review, the Passport is then subjected to a review by three (3) Experts including the Expert who conducted the initial review.

d) In case of a “Likely doping” consensus of the three (3) Experts, the process continues with the creation of an Athlete Biological Passport Documentation Package.

e) An Adverse Passport Finding is reported by the Athlete Passport Management Unit to the Passport Custodian if the Experts’ opinion is maintained after review of all information available at that stage, including the Athlete Biological Passport's report in ADAMS.
C.2 Initial Review Phase

C.2.1 Review by the Adaptive Model

C.2.1.1 In ADAMS, the Adaptive Model automatically processes data on the biological Markers of the Athlete Biological Passport. These Markers include primary Markers that are defined as the most specific to doping and secondary Markers that provide supporting evidence of doping in isolation or in combination with other Markers. The Adaptive Model predicts for an individual an expected range within which a series of Marker values falls assuming a normal physiological condition. Outliers correspond to those values outside of the 99%-range, from a lower limit corresponding to the 0.5th percentile to an upper limit corresponding to the 99.5th percentile (1:100 chance or less that this result is due to normal physiological variation). A specificity of 99% is used to identify both haematological and steroidal Atypical Passport Findings. In the case of sequence deviations (sequence Atypical Passport Findings), the applied specificity is 99.9% (1:1000 chance or less that this is due to normal physiological variation).

C.2.1.2 An Atypical Passport Finding is a result generated by the Adaptive Model in ADAMS which identifies either a primary Marker(s) value(s) as being outside the Athlete’s intra-individual range or a longitudinal profile of a primary Marker values (sequence deviations) as being outside expected ranges, assuming a normal physiological condition. An Atypical Passport Finding requires further attention and review.

C.2.1.3 The Athlete Passport Management Unit may also submit a Passport to the Expert when there is no Atypical Passport Finding (see C.2.2.4 below).

C.2.1.4 Atypical Passport Finding – Haematological Module

C.2.1.4.1 For the Haematological Module, the Adaptive Model predicts for an individual an expected range within which a series of Marker values falls assuming a normal physiological condition. Outliers correspond to those values outside of the 99%-range, from a lower limit corresponding to the 0.5th percentile to an upper limit corresponding to the 99.5th percentile (1:100 chance or less that this result is due to normal physiological variation). A specificity of 99% is used to identify both haematological and steroidal Atypical Passport Findings. In the case of sequence deviations (sequence Atypical Passport Findings), the applied specificity is 99.9% (1:1000 chance or less that this is due to normal physiological variation).

C.2.1.2 A アスリート・バイオロジカル・パスポートに基づく非定型報告は、通常の生理的状態であると仮定した上で、主要評価項目の値が動作者の個人内変動の範囲外であるか、又は副次評価項目の値の長期的なプロファイルが予期された範囲外であること（連続した逸脱を伴う場合）を示す。アスリート・バイオロジカル・パスポートに基づく非定型報告は、さらに注意と審査が必要である。

C.2.1.3 アスリート・パスポート・マネジメント・ユニットは、アスリート・バイオロジカル・パスポートに基づく非定型報告がない場合（以下の C.2.4 を参照すること。）にも、エキスパートにパスポートを提出することができる。

C.2.1.4 アスリート・バイオロジカル・パスポートに基づく非定型報告—血液モジュール

C.2.1.4.1 血液モジュールについて、Adaptive Model は、
The Athlete Passport Management Unit should also provide subjected to analysis for Agents Affecting Erythropoiesis. An Atypical Passport Finding is generated when a HGB and/or OFFS value of the last test falls outside the expected intra-individual ranges. Furthermore, the longitudinal profile composed of (up to) the last five valid HGB and/or OFFS values is also considered as atypical when deviating from the expected ranges, as determined by the Adaptive Model. An Atypical Passport Finding is only generated by the Adaptive Model based on values of the primary Markers HGB and OFFS or the sequence thereof.

C.2.1.4.2 In case of an Atypical Passport Finding the Athlete Passport Management Unit shall advise the Results Management Authority (or Testing Authority as applicable) in the Athlete Passport Management Unit report, or via the Passport Custodian where appropriate, on whether the Sample, or any accompanying urine Sample, should be subjected to analysis for Agents Affecting Erythropoiesis. The Athlete Passport Management Unit should also provide recommendations for Agents Affecting Erythropoiesis analysis when the Adaptive Model detects an abnormality in the secondary Markers RET% and/or OFFS.

C.2.1.5 Atypical Passport Finding – Steroidal Module

C.2.1.5.1 For the Steroidal Module, the Adaptive Model automatically processes in ADAMS one primary Marker, the T/E ratio, and four (4) secondary Markers, the ratios A/T, A/Etio, 5αAdiol/5βAdiol and 5βAdiol/E.

C.2.1.5.2 Ratios coming from a Sample that showed signs of heavy microbial degradation, and ratios for which one or both of the concentrations were not measured accurately by the Laboratory as established in the Technical Document for Endogenous Anabolic Androgenic Steroids (TDEAAS), shall not be processed by the Adaptive Model. In the case where the Laboratory reports a confounding factor that may otherwise cause an alteration in the steroid profile, such as the presence of ethanol glucuronide in the Sample, the Athlete Passport Management Unit shall evaluate whether the steroid profile can still be considered as valid and processed by the Adaptive Model and the Sample be subjected to a Confirmation Procedure (see TDEAAS).

C.2.1.5.3 An Atypical Passport Finding is generated when a value of the T/E ratio falls outside the expected intra-individual ranges. In addition, the "longitudinal steroid profile" composed of (up to) the last five (5) valid values of the T/E ratio is also considered as atypical when deviating from the expected ranges, as determined by the Adaptive Model automatically processes in ADAMS two primary Markers, haemoglobin concentration (HGB) and stimulation index OFF-score (OFFS), and two secondary Markers, the reticulocyte percentage (RET%) and the Abnormal Blood Profile Score (ABPS). An Atypical Passport Finding is generated when a HGB and/or OFFS value of the last test falls outside the expected intra-individual ranges. Furthermore, the longitudinal profile composed of (up to) the last five valid HGB and/or OFFS values is also considered as atypical when deviating from the expected ranges, as determined by the Adaptive Model. An Atypical Passport Finding is only generated by the Adaptive Model based on values of the primary Markers HGB and OFFS or the sequence thereof.

C.2.1.4.2 アスリート・バイオロジカル・パスポートに基づく非定型報告の場合には、アスリート・パスポート・マネジメント・ユニットは、検体又は付随する尿検体が赤血球造血に影響を与える物質の分析の対象となるべきか、検体管理機関（又は該当する場合には検査管理機関）に対し、アスリート・パスポート・マネジメント・ユニットで、アスリート・バイオロジカル・パスポートに基づく非定型報告の場合は、アスリート・パスポートの受付機関に連絡するものとする。また、アスリート・パスポート・マネジメント・ユニットは、Adaptive Model が二次的マークーRET%及び又は OFFS に異常を発見した場合には、赤血球造血に影響を与える物質の分析のために、勧告を提供すべきである。

C.2.1.5 アスリート・バイオロジカル・パスポートに基づく非定型報告ーステロイド・モジュール

C.2.1.5.1 ステロイド・モジュールに関しては、主要評価項目、T/E の比率、及び 4 つの副次評価項目、A/T、A/Etio、5α Adiol/5β Adiol 及び 5α Adiol/E の比率を自動的に処理する。

C.2.1.5.2 微生物による重大な変質の兆候を示した検体から生ずる比率、及び、内因性薬物同化男性化ステロイド薬のためのテクニカルキュメント(TDEAAS)が定めるところに従い、一方又は両方の密度が分析機関により正確に測定されなかった比率は、適用モデルによって処理されてはならない。分析機関が、検体においてグルコリドエタノールの存在といったステロイドプロファイルの変化を別途引き起こす要因を報告する場合、アスリート・パスポート・マネジメント・ユニットは、ステロイドプロファイルが引き続き有効であり、適用モデルによって処理することが可能か否か及び、検体の確認分析手続（TDEAAS 参照）に入るべきか否かを評価するものとする。
C.2.1.5.4 In the case of a “longitudinal steroidal profile”, an Atypical Passport Finding caused by an atypically high T/E value will trigger an Atypical Passport Finding Confirmation Procedure Request notification through ADAMS as established in the TDEAAS. When the Adaptive Model determines an abnormality in any of the other ratios of the “steroid profile” (A/T, A/Etio, 5αAdiol/5βAdiol and 5βAdiol/E), the Athlete Passport Management Unit should advise the Results Management Authority (or Testing Authority as applicable) in the Athlete Passport Management Unit report, or via the Passport Custodian where applicable, on whether the Sample should be subjected to a Confirmation Procedure.

C.2.1.6 Suspicious Steroid Profiles - Steroidal Module

C.2.1.6.1 If the Sample constitutes the first and unique result in a Passport, or if the Sample cannot be matched to a Doping Control Form in ADAMS, ADAMS will flag the result as a Suspicious Steroid Profile (SSP) if the steroid profile of the Sample meets any of the SSP criteria established in the TD EAAS, and the Laboratory and the Testing Authority will receive an SSP-Confirmation Procedure Request (CPR) notification from ADAMS. In such cases, the Testing Authority, upon consultation by the Laboratory, shall confirm, in writing within seven (7) days, whether or not the SSP result shall be confirmed by the Laboratory. The Testing Authority may consult with their APMU, or the Passport Custodian where applicable, in order to reach a decision. If the Testing Authority advises the Laboratory not to proceed with Confirmation Procedures, then it shall provide the reasons for this decision to the Laboratory, which shall update the ADAMS test report for the Sample accordingly. In the absence of any justification from the Testing Authority, the Laboratory shall proceed with the confirmation analyses (for further details, see TD EAAS).

C.2.1.7 Departure from WADA Athlete Biological Passport requirements

C.2.1.7.1 If there is a departure from WADA Athlete Biological Passport requirements for Sample collection, transport and analysis, the biological Marker result obtained from this Sample affected by the non-conformity shall not be considered in the Adaptive Model calculations (for example, RET% can be affected but not HGB under certain transportation conditions).

C.2.1.7.2 A Marker result which is not affected by the non-conformity can still be considered in the Adaptive Model calculations. In such case, the Athlete Passport Management Unit shall provide the specific explanations.
supporting the inclusion of the result(s). In all cases, the Sample shall remain recorded in the Athlete’s Passport. The Experts may include all results in their review provided that their conclusions may be validly supported when taking into account the effects of the non-conformity.

C.2.2 The Initial Expert Review

C.2.2.1 A Passport generating an Atypical Passport Finding, or for which a review is otherwise justified, shall be sent by the Athlete Passport Management Unit to an Expert for review in ADAMS. This should take place within seven (7) days following the generation of the Atypical Passport Finding in ADAMS. The review of the Passport shall be conducted based on the Passport and other basic information (e.g. Competition schedules), which may be available, such that the Expert is blinded to the identity of the Athlete.

[Comment to Article C.2.2.1: If a result rendered by a Laboratory represents an Atypical Passport Finding caused by an atypically high T/E value, the Sample will undergo a Confirmation Procedure, including GC/C/IRMS analysis. If the result of the GC/C/IRMS Confirmation Procedure is negative or inconclusive then the Athlete Passport Management Unit shall seek an Expert review. An Athlete Passport Management Unit or Expert review is not required when the GC/C/IRMS Confirmation Procedure renders an Adverse Analytical Finding (AAF).]

C.2.2.2 If a Passport has been recently reviewed by an Expert and the Passport Custodian is in the process of executing a specific multi-Sample Testing strategy on the Athlete, the Athlete Passport Management Unit may delay the review of a Passport generating an Atypical Passport Finding triggered by one of the Samples collected in this context until completion of the planned series of tests. In such situations, the Athlete Passport Management Unit shall clearly indicate the reason for delaying the review of the Passport in the Athlete Passport Management Unit report.

C.2.2.3 If the first and unique result in a Passport is flagged as an Atypical Passport Finding by the Adaptive Model, the Athlete Passport Management Unit may recommend the collection of an additional Sample before initiating the initial Expert review.

C.2.2.4 Review in the absence of an Atypical Passport Finding

C.2.2.4.1 A Passport may also be sent for Expert review in the absence of an Atypical Passport Finding where the Passport includes other elements otherwise justifying a
These elements may include, without limitation:

a) Data not considered in the Adaptive Model;

b) Any abnormal levels and/or variations of Marker(s);

c) Signs of hemodilution in the haematological Passport;

d) Steroid levels in urine below the corresponding Limit of Quantification of the assay;

e) Intelligence in relation to the Athlete concerned.

C.2.2.4.2 An Expert review initiated in the above-mentioned situations may result in the same consequences as an Expert review triggered by an Atypical Passport Finding.

C.2.2.5 Expert Evaluation

C.2.2.5.1 When evaluating a Passport, an Expert weighs the likelihood that the Passport is the result of the Use of a Prohibited Substance or Prohibited Method against the likelihood that the Passport is the result of a normal physiological or pathological condition in order to provide one of the following opinions: “Normal”, “Suspicious”, “Likely doping” or “ Likely medical condition”. For a “Likely doping” opinion, the Expert shall come to the conclusion that the likelihood that the Passport is the result of the Use of a Prohibited Substance or Prohibited Method outweighs the likelihood that the Passport is the result of a normal physiological or pathological condition.

[Comment to Article C.2.2.5.1: When evaluating competing propositions, the likelihood of each proposition is evaluated by the Expert based on the evidence available for that proposition. It is acknowledged that it is the relative likelihoods (i.e., likelihood ratio) of the competing propositions that ultimately determine the Expert’s opinion. For example, where the Expert is of the view that a Passport is highly likely the result of the Use of a Prohibited Substance or Prohibited Method, it is necessary for a “Likely doping” evaluation that the Expert consider that it is unlikely that it may be the result of a normal physiological or pathological condition. Similarly, where the Expert is of the view that a Passport is likely the result of the Use of a Prohibited Substance or Prohibited Method, it is necessary for a “Likely doping” evaluation that the Expert consider that it is highly unlikely that it may be the result of a normal physiological or pathological condition.]

C.2.2.5.2 To reach a conclusion of “Likely doping” in the absence of an Atypical Passport Finding, the Expert shall come to the opinion that it is highly likely that the Passport is the result of the Use of a Prohibited Substance or Prohibited Method...
Method and that it is highly unlikely that the Passport is the result of a normal physiological or pathological condition.

C.2.3 Consequences of the Initial Review

Depending on the outcome of the initial review, the Athlete Passport Management Unit will take the following action:

<table>
<thead>
<tr>
<th>Expert Evaluation</th>
<th>Athlete Passport Management Unit Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Normal”</td>
<td>Continue normal Testing plan.</td>
</tr>
<tr>
<td>“Suspicious”</td>
<td>Provide recommendations to the Passport Custodian for Target Testing, Sample analysis and/or requesting further information as required.</td>
</tr>
<tr>
<td>“Likely doping”</td>
<td>Send to a panel of three (3) Experts, including the initial Expert, as per section C.2 of this Annex C.</td>
</tr>
<tr>
<td>“Likely medical condition”</td>
<td>Inform the Athlete as soon as possible via the Passport Custodian (or send to other Experts).</td>
</tr>
</tbody>
</table>

[Comment to Article C.2.3: The Athlete Biological Passport is a tool to detect the possible Use of Prohibited Substance(s) or Prohibited Method(s) and it is not intended as a health check or for medical monitoring. It is important that the Passport Custodian educates the Athletes to ensure that they undergo regular health monitoring and not rely on the Athlete Biological Passport for this purpose. Nevertheless, the Passport Custodian should inform the Athlete in case the Passport indicates a likely pathology as determined by the Experts.]

C.3 Review by Three (3) Experts

C.3.1 In the event that the opinion of the appointed Expert in the initial review, pending other explanation to be provided at a later stage, is that of “Likely doping”, the Passport shall then be sent by the Athlete Passport Management Unit to two (2) additional Experts for review. This should take place within seven (7) days after the reporting of the initial review. These additional reviews shall be conducted without knowledge of the initial review. These three (3) Experts now constitute the Expert Panel, composed of the Expert appointed in the initial review and these two (2) other Experts.

C.3.2 The review by the three (3) Experts must follow the same procedure, where applicable, as presented in section C.2.3. 先期調査の結果に応じて、アスリート・パスポート・マネジメント・ユニットは以下の措置をとる。

<table>
<thead>
<tr>
<th>エキスパートの評価</th>
<th>アスリート・パスポート・マネジメント・ユニットの措置</th>
</tr>
</thead>
<tbody>
<tr>
<td>「正常」</td>
<td>通常の検査計画を継続する。</td>
</tr>
<tr>
<td>「疑わしい」</td>
<td>必要に応じて、特定対象検査、検体分析及び／又は更なる情報を要請するためにパスポート保有機関に勧告する。</td>
</tr>
<tr>
<td>「ドーピングの可能性濃厚」</td>
<td>本付属文書 CのC.2項に従い、最初のエキスパートを含む、3名のエキスパートにより構成されるパネルに、パスポートを送付する。</td>
</tr>
<tr>
<td>「医学的状態の可能性」</td>
<td>パスポート保有機関を通じて可及的速やかに競技者に通知する（又は他のエキスパートに送付する。）。</td>
</tr>
</tbody>
</table>

C.3.3 3名のエキスパートによる審査

C.3.3.1 後続の段階で提供される他の説明を待って、初期審査において任命されたエキスパートが「ドーピングの可能性濃厚」と考える場合には、パスポートは、審査のために、アスリート・パスポート・マネジメント・ユニットから2名の追加のエキスパートに送付されるものとする。これは初期審査の報告から7日以内に行われるべきである。これらの追加の審査は、初期審査についての情報なく行われるものとする。これら3名のエキスパートは、直ちに、初期審査で任命されたエキスパート及びこれら2名の他のエキスパートにより構成される「エキスパートパネル」を構成する。

C.3.2 3名のエキスパートによる審査は、本付属文書 C.2項で示されたものと同じ手続きに従わなければならない。
C.2.2 of this Annex. The three (3) Experts shall each provide their individual reports in ADAMS. This should take place within seven (7) days after receipt of the request.

C.3.3 The Athlete Passport Management Unit is responsible for liaising with the Experts and for advising the Passport Custodian of the subsequent Expert assessment. The Experts can request further information, as they deem relevant for their review, notably information related to medical conditions, Competition schedule and/or Sample(s) analysis results. Such requests are directed via the Athlete Passport Management Unit to the Passport Custodian.

C.3.4 A unanimous opinion among the three (3) Experts is necessary in order to proceed further towards declaring an Adverse Passport Finding, which means that all three (3) Experts render an opinion of “Likely doping”. The conclusion of the Experts must be reached with the three (3) Experts assessing the Athlete’s Passport with the same data.

[Comment to Article C.3.4: The three (3) Expert opinions cannot be accumulated over time based on different data.]

C.3.5 To reach a conclusion of “Likely doping” in the absence of an Atypical Passport Finding, the Expert Panel shall come to the unanimous opinion that it is highly likely that the Passport is the result of the Use of a Prohibited Substance or Method and that there is no reasonably conceivable hypothesis under which the Passport is the result of a normal physiological condition and highly unlikely that it is the result of pathological condition.

C.3.6 In the case when two (2) Experts evaluate the Passport as “Likely doping” and the third Expert as “Suspicious” asking for more information, the Athlete Passport Management Unit shall confer with the Expert Panel before they finalize their opinion. The group can also seek advice from an appropriate outside Expert, although this must be done while maintaining strict confidentiality of the Athlete’s Personal Information.

C.3.7 If no unanimity can be reached among the three (3) Experts, the Athlete Passport Management Unit shall report the Passport as “Suspicious”, update the Athlete Passport Management Unit report, and recommend that the Passport Custodian pursue additional Testing and/or gather intelligence on the Athlete (refer to Information Gathering and Intelligence Sharing Guidelines), as appropriate.
C.4 Conference Call, Compilation of the Athlete Biological Passport Documentation Package and Joint Expert Report

C.4.1 If a unanimous opinion of “Likely doping” is rendered by all three (3) Experts, the Athlete Passport Management Unit shall declare a “Likely doping” evaluation in the Athlete Passport Management Unit report in ADAMS and should organize a conference call with the Expert Panel to initiate the next steps for the case, including proceeding with the compilation of the Athlete Biological Passport Documentation Package (see Technical Document for Athlete Passport Management Units) and drafting of the joint Expert report. In preparation for this conference call, the Athlete Passport Management Unit should coordinate with the Passport Custodian to compile any potentially relevant information to share with the Experts (e.g., suspicious analytical findings, relevant intelligence and relevant pathophysiological information).

C.4.2 Once completed, the Athlete Biological Passport Documentation Package shall be sent by the Athlete Passport Management Unit to the Expert Panel, who will review it and provide a joint Expert report to be signed by all three (3) Experts. The conclusion within the joint Expert report shall be reached without interference from the Passport Custodian. If necessary, the Expert Panel may request complementary information from the Athlete Passport Management Unit.

C.4.3 At this stage, the identity of the Athlete is not mentioned but it is accepted that specific information provided may allow to identify the Athlete. This shall not affect the validity of the process.

C.5 Issuing an Adverse Passport Finding

C.5.1 If the Expert Panel confirms their unanimous position of “likely doping”, the Athlete Passport Management Unit shall declare an Adverse Passport Finding in ADAMS that includes a written statement of the Adverse Passport Finding, the Athlete Biological Passport Documentation Package and the joint Expert report.

C.5.2 After reviewing the Athlete Biological Passport Documentation Package and joint Expert report, the Passport Custodian shall:

a) Notify the Athlete of the Adverse Passport Finding in accordance with Article 5.3.2 of International Standard for

C.5.3 This stage in which the identity of the Athlete, if not mentioned, is accepted that specific information provided may be used to identify the Athlete. This shall not affect the validity of the process.

C.5.4 The Passport Custodian shall:

a) 「結業管理に関する国際基準」の第 5.3.2 項に従い、競技者に対して、アスリート・バイオロジカル・パスポートに基づく違反が疑われる報告を ADAMS において宣言するものとする。
Results Management;

b) Provide the Athlete the Athlete Biological Passport Documentation Package and the joint Expert report;

c) Invite the Athlete to provide their own explanation, in a timely manner, of the data provided to the Passport Custodian.

C.6 Review of Explanation from Athlete and Disciplinary Proceedings

C.6.1 Upon receipt of any explanation and supporting information from the Athlete, which should be received within the specified deadline, the Athlete Passport Management Unit shall forward it to the Expert Panel for review with any additional information that the Expert Panel considers necessary to render its opinion in coordination with both the Passport Custodian and the Athlete Passport Management Unit. At this stage, the review is no longer anonymous. The Expert Panel shall reassess or reassert the case and reach one of the following conclusions:

a) Unanimous opinion of “Likely doping” by the Experts based on the information in the Passport and any explanation provided by the Athlete; or

b) Based on the available information, the Experts are unable to reach a unanimous opinion of “Likely doping” set forth above.

[Comment to Article C.6.1: Such a reassessment shall also take place when the Athlete does not provide any explanation.]

C.6.2 If the Expert Panel expresses the opinion set forth in section C.6.1(a), then the Passport Custodian shall be informed by the Athlete Passport Management Unit, shall charge the Athlete in accordance with Article 7 of the International Standard for Results Management and continue with Results Management in accordance the International Standard for Results Management.

C.6.3 If the Expert Panel expresses the opinion set forth in section C.6.1(b), the Athlete Passport Management Unit shall update the Athlete Passport Management Unit report and recommend the Passport Custodian to pursue additional Testing and/or gather intelligence on the Athlete (refer to Information Gathering and Intelligence Sharing Guidelines), as appropriate. The Passport Custodian shall notify the Athlete and WADA of the outcome of the review.

C.7 Passport Re-setting

C.7.1 In the event the Athlete has been found to have committed an anti-doping rule violation based on the Passport, the Athlete’s Passport shall be reset by the Passport Custodian.

b) 競技者に対し、アスリート・バイオロジカル・パスポート書類及び共同エキスパート報告を提供する。

c) パスポート保有機関に提供されたデータについて、競技者が、適時に自身の釈明を行うよう、当該競技者に勧める。
Custodian at the start of the relevant period of Ineligibility and a new Biological Passport ID shall be assigned in ADAMS. This maintains the Athlete’s anonymity for potential Athlete Passport Management Unit and Expert Panel reviews conducted in the future.

C.7.2 When an Athlete is found to have committed an anti-doping rule violation on any basis other than the Athlete Biological Passport, the haematological and/or Steroidal Passport will remain in effect, except in those cases where the Prohibited Substance or Prohibited Method caused an alteration of the haematological or steroidal Markers, respectively (e.g. for AAF reported for anabolic androgenic steroids, which may affect the Markers of the steroid profile, or for the Use of ESAs or blood transfusions, which would alter the haematological Markers). The Passport Custodian shall consult with their Athlete Passport Management Unit following an Adverse Analytical Finding to determine whether a Passport reset is warranted. In such instances, the Athlete’s profile(s) would be reset from the time of the beginning of the sanction.